Activity and Mode of Action for Methacrylate Polymers as Antimicrobial Agents against Staphylococcus aureus. by Thoma, Laura Marjorie
  
 
 
 
 
 
 
 
 
Activity and Mode of Action for Methacrylate Polymers as Antimicrobial Agents against 
Staphylococcus aureus 
 
by 
 
Laura Marjorie Thoma 
 
 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
(Chemistry) 
in The University of Michigan 
2014 
 
 
 
 
 
 
 
 
 
 
 
 
Doctoral Committee: 
 
 Assistant Professor Kenichi Kuroda, Chair 
 Associate Professor Anne J. McNeil 
Professor Ayyalusamy Ramamoorthy 
 Associate Professor Chuanwu Xi 
  
 
 
 
 
 
 
 
 
© Laura Marjorie Thoma 
All rights reserved 
2014 
 
ii 
 
DEDICATION 
To family and friends for their love, encouragement, and support. Always. 
 
 iii 
 
ACKNOWLEDGEMENTS 
I would like to thank my research advisor, Professor Kenichi Kuroda for his assistance, 
encouragement, and thoughtful discussions. He provided me guidance in meeting scientific and 
intellectual challenges, and I sincerely appreciate all his effort and support these past five years.  
Thank you to my committee members Professor Anne J. McNeil, Professor Ayyalusamy 
Ramamoorthy, and Professor Chuanwu Xi for their helpful comments and guidance during my 
time at Michigan. 
Thanks to my coworkers in the Kuroda lab for their help and support. Thanks to Dr. 
Haruko Takahashi for her assistance with cell culture, as well as antimicrobial and hemolytic 
testing for the polymers in Chapter 4. I would also like to thank Dr. Edmund Palermo for his 
optimization of the RAFT polymerization conditions of Chapter 2 and Dr. Enrico Nadres for the 
polymer synthesized in Chapter 4.  
I would like to acknowledge my collaborator Professor Blaise R. Boles, who provided S. 
aureus strains, performed in vivo testing, and was a great resource for S. aureus questions. I 
would like to thank Professor Eric Krukonis for his assistance and advice on cell culture. I would 
also like to acknowledge Professor Robert Davenport of the University of Michigan Hospital 
who generously supplied units of human red blood cells for this work.  
This research was supported by the Department of Biologic and Materials Sciences, 
University of Michigan School of Dentistry, the NSF CAREER Award (DMR-0845592 as well 
as the National Center for Advancing Translational Studies of the National Institutes of Health 
 iv 
 
under award no. 2UL1TR000433 through the Michigan Institute for Clinical and Health 
Research (MICHR).  
Finally, I would like to gratefully acknowledge my parents, George and Margie Thoma, 
and my sister Elizabeth Thoma, who inspire and encourage me to follow my dreams. Thanks to 
my husband, Yingda Ye, for his constant love and support. My life is better every day because 
you are a part of it.  
 
 v 
 
TABLE OF CONTENTS 
DEDICATION ii 
ACKNOWLEDGEMENTS iii 
LIST OF TABLES vii 
LIST OF FIGURES viii 
LIST OF APPENDICES xi 
LIST OF ABBREVIATIONS xii 
Chapter 1 : Introduction 1 
Antibiotic Resistance 1 
New Antibiotic Design: Host-Defense Antimicrobial Peptides. 2 
Antimicrobial Polymers 4 
Challenge: Antimicrobial Polymers with Cell-specificity 7 
Chapter 2 : Assessment of in vivo Activity of Methacrylate Homopolymers for Treatment 
of Staphylococcus aureus Nasal Colonization 11 
Introduction 11 
Polymer Synthesis and Characterization 13 
Antimicrobial Activity 16 
Membrane Depolarization Assay 18 
Cell Leakage Assay 21 
Antimicrobial Activity in the Presence of Serum 24 
Bactericidal Kinetics 26 
Resistance Development 28 
Hemolytic Activity 29 
Cell Cytotoxicity 30 
Selectivity to Bacteria Over Mammalian Cells 33 
In vivo Antimicrobial Activity of AEMPs 33 
Conclusions 36 
Chapter 3 : Methacrylate Homopolymers as Cell Wall Targeting Antimicrobials 38 
 vi 
 
Introduction 38 
Polymer Synthesis and Characterization 41 
Antimicrobial Activity 44 
Antimicrobial Activity in the Presence of Serum 49 
Hemolytic Activity 51 
Activity against S. aureus Mutants 52 
Conclusion 54 
Chapter 4 : Antimicrobial Action of Amphiphilic Copolymers Targeting Bacterial Cell 
Membranes 57 
Background and Previous Results: Osmolysis of Red Blood Cells 57 
Current Efforts 60 
Polymer Synthesis and Characterization 61 
The Effect of Osmolytes on Antimicrobial Activity of Polymers 62 
Conclusion 65 
Chapter 5 : Conclusions and Future Directions 66 
APPENDICES 73 
REFERENCES 91 
 vii 
 
LIST OF TABLES 
Table 2-1. Synthesis and Characterization of Boc-protected AEMPs. 16 
Table 2-2. The antimicrobial spectrum of AEMPs and antibiotics. 17 
Table 2-3. Absorbance of assay solutions. 22 
Table 2-4. The antimicrobial activity of AEMPs in the presence of fetal bovine serum. 24 
Table 2-5. Cytotoxicity of AEMPs to HEp-2 and COS-7 cells. 31 
Table 2-6. Selectivity of AEMPs to S. aureus over mammalian cells. 33 
Table 3-1. Synthesis and Characterization of Polymers with Primary ammonium groups 43 
Table 3-2. Synthesis and Characterization of Polymers with Quaternary ammonium groups. 44 
Table 3-3. The antimicrobial spectrum and hemolysis of polymers with primary and quaternary 
ammonium groups. 46 
Table 3-4. The antimicrobial activity of P20 and Q19 in the presence of fetal bovine serum. 50 
Table 4-1. Characterization and Activity of Amphiphilic Methacrylate Polymers and Controls  62 
Table 4-2. Osmolytes and their hydrodynamic radii 63 
Table D-1. In vivo Testing 90 
 viii 
 
LIST OF FIGURES 
Figure 1-1. Representative antibiotics: penicillin, norfloxacin, and vancomycin. 2 
Figure 1-2. Structure of magainin-2, an α-helical cationic antimicrobial peptide. 3 
Figure 1-3. Proposed mechanisms of membrane disruption exerted by antimicrobial peptides. 3 
Figure 1-4. Representative antimicrobial Polymers. 6 
Figure 1-5. Segregated amphiphilic conformation of amphiphilic polymers in bacterial 
membranes. 6 
Figure 1-6. Antimicrobial activity of PEIs. 8 
Figure 1-7. Cationic polymers with anti-S. aureus activity. 9 
Figure 2-1. Synthesis of ammonium ethyl methacrylate homopolymers (AEMPs). 14 
Figure 2-2. GPC Trace of Boc-protected polymers 15 
Figure 2-3. 
1
H NMR spectrum of Boc-P9.9 15 
Figure 2-4. Minimum inhibitory concentrations of AEMPs for selected Gram-positive and 
Gram-negative bacteria. 17 
Figure 2-5. Fluorescence intensity of DiSC3(5) in the presence of AEMP and LPEI. 19 
Figure 2-6. S. aureus membrane depolarization by LPEI and AEMP. 20 
Figure 2-7. Detection of UV-absorbing cellular components. 23 
Figure 2-8. The effect of FBS on the activity of AEMPs and mupirocin against S. aureus strains.
 25 
 ix 
 
Figure 2-9. Bactericidal kinetics of AEMPs and antibiotics mupirocin and norfloxacin at 2 times 
MIC. 27 
Figure 2-10. Propensity of AEMP P7.7 for resistance development in S. aureus. 29 
Figure 2-11. Hemolytic activity of AEMPs against human red blood cells. 30 
Figure 2-12. Cytotoxicity of AEMPs. 31 
Figure 2-13. In vivo assessment in a cotton rat nasal S. aureus colonization model. 35 
Figure 3-1. Comparison of Gram-positive and Gram-negative bacterial membranes. 39 
Figure 3-2. Teichoic acid polymers are located within the Gram-positive cell wall. 40 
Figure 3-3. S. aureus wall teichoic acids (WTAs) 40 
Figure 3-4. Synthesis of ammonium ethyl methacrylate homopolymers with primary ammonium 
groups. 42 
Figure 3-5. 
1
H NMR spectrum of Polymer with Primary ammonium groups 42 
Figure 3-6. Synthesis of ammonium ethyl methacrylate homopolymers with quaternary 
ammonium groups. 43 
Figure 3-7. 
1
H NMR spectrum of Polymer with quaternary ammonium groups. 44 
Figure 3-8. Activity spectrum of A) Polymers with Primary Ammonium groups (P-polymers) 
and B) Polymers with Quaternary Ammonium groups (Q-polymers). 47 
Figure 3-9. Minimum inhibitory concentrations of polymer with primary ammonium groups P17 
and polymer with quaternary ammonium groups Q19 against selected bacteria. 48 
Figure 3-10. The effect of FBS on the activity of P17 and Q19 against E. coli and S. aureus. 50 
Figure 3-11. Boc deprotection by TFA 51 
Figure 3-12. Hemolytic activity of AEMPs against human red blood cells. 52 
Figure 3-13. MIC of P17 and Q19 against S. aureus and bacterial mutants. 54 
 x 
 
Figure 4-1. Structure of Amphiphilic Methacrylate Random Copolymers. 57 
Figure 4-2. Osmoprotection against hemolysis induced by melittin. 59 
Figure 4-3. Osmoprotection against hemolysis induced by the copolymers and melittin. 60 
Figure 4-4. Structure of Amphiphilic Methacrylate Polymers. 62 
Figure 4-5. Osmoprotection against hemolysis induced by the polymers and PEIs. 64 
Figure A-1. Synthesis of monomer 2-(tert-butoxycarbonylamino) ethyl methacrylate 74 
Figure B-1. 
1
H NMR peak assignments for polymers with primary ammonium side chains 
synthesized by RAFT polymerization. 85 
Figure B-2. 
1
H NMR of Boc-P9.9 (DMSO-d6) 86 
Figure B-3. 
1
H NMR of P7.7 (DMSO-d6) 86 
Figure B-4. 
1
H NMR of Boc-P11 (DMSO-d6) 86 
Figure B-5. 
1
H NMR of P10 (DMSO-d6) 87 
Figure B-6. 
1
H NMR of Boc-P19 (DMSO-d6) 87 
Figure B-7. 
1
H NMR of P12
 
(DMSO-d6) 87 
Figure C-1. NMR of CPETC at t = 0 (CDCl3) 88 
Figure C-2. CPETC + TFA at t = 5 (CDCl3) 89 
Figure C-3. CPETC + TFA at t = 30 min (CDCl3) 89 
 
 
 
 
 
 
 xi 
 
LIST OF APPENDICES 
APPENDIX A 73 
APPENDIX B 85 
APPENDIX C 88 
APPENDIX D 90 
 
 
 xii 
 
LIST OF ABBREVIATIONS 
AEMA  aminoethyl methacrylate 
AIBN   azo-bis-isobutyronitrile 
CPETC  2-cyanoprop-s-yl ethyl trithiocarbonate 
CTAB   cetyltrimethylammonium bromide 
Ð   polydispersity 
EMA   ethyl methacrylate 
FITC   fluorescein isothiocyanate 
GPC   gel permeation chromatography 
HC50   hemolytic concentration 
HDP   host defense peptide 
IC50   cytotoxic concentration 
MBC   minimum bactericidal concentration 
MHB   Mueller Hinton broth 
MIC   minimum inhibitory concentration 
MMA   methyl methacrylate 
MMP   methyl mercaptopropionate 
MW   molecular weight 
NMR   nuclear magnetic resonance 
PBS   phosphate buffered saline 
PEG   polyethylene glycol 
PEI   polyethyleneimine 
RAFT   reversible addition-fragmentation chain-transfer polymerization 
RBC   red blood cell 
TFA   trifluoroacetic acid 
TSB   tryptone soya broth 
 
  
 1 
 
Chapter 1 : Introduction 
Antibiotic Resistance 
There is an urgent need for new antimicrobials due to the increasing number of drug-resistant 
bacterial infections worldwide.
1, 
2,
 
3,
 
4
 The report from US Centers for Disease Control and 
Prevention (CDC) in 2013 indicates that in the US each year, at least 2 million people become 
infected with bacteria that are resistant to antibiotics, resulting in no less than 23,000 deaths and 
an estimated $20 billion in healthcare costs.
5
 With such a tremendous impact on human health 
and well being, there is a compelling need for antimicrobials to combat antibiotic resistant 
bacteria due to the lack of new antibiotics in the development pipelines.   
Modern antibiotics either act on processes that are unique to bacteria, such as the synthesis of 
cell walls, or act on bacterium-specific targets.
6
 Most current bactericidal antimicrobials inhibit 
DNA synthesis
7
, RNA synthesis
8
, cell wall synthesis
9
, or protein synthesis
10
. Examples of 
several antibiotics include Penicillin, Norfloxacin, and Vancomycin (Figure 1-1). While there are 
a large number of antibiotics available on the market today, many bacteria have already 
developed antibiotic resistance to these drugs. Drug resistance typically arises through 
mechanisms that block the interaction of a drug and its target. Bacteria achieve drug resistance 
through genetic mutation of the antimicrobial target, enzymatic deactivation of the drug, or loss 
of an enzyme required to activate a prodrug. Bacteria also work to prevent the drug from 
reaching its target by exporting the drug using efflux pumps or making small structural changes 
that reduce the bacterial cell’s permeability of the drug.  
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Figure 1-1. Representative antibiotics: penicillin, norfloxacin, and vancomycin. 
 
New Antibiotic Design: Host-Defense Antimicrobial Peptides. 
To find inspiration for antimicrobials that are less likely to cause resistance development, 
scientists looked to nature and found a solution in host-defense peptides.
11
 Host-defense peptides 
are small molecules that are a component of the innate immune system. These peptides present 
antibacterial, antifungal, antiparasitic, or antiviral activity.
12,
 
13
 Host-defense peptides are 
attractive as new antimicrobials due to their broad spectrum of activity, rapid bactericidal action, 
and low propensity for resistance development in bacteria. The host-defense peptides have also 
been recognized as “antimicrobial peptides” due to their antimicrobial functions.  In the field, the 
peptides are referred to as “host-defense peptides” when the focus is on the function of the 
peptides in the innate immune system. When the antimicrobial activity of peptides is the interest 
of research the term “antimicrobial peptides” is used. As our research focuses on the 
antimicrobial activity of peptides and polymers, the term antimicrobial peptides (AMPs) will be 
used to refer to the peptides. One AMP is Magainin-2, an antimicrobial peptide found in the 
African clawed frog Xenopus laevis (Figure 1-2).  
 3 
 
 
Figure 1-2. Structure of magainin-2, an α-helical cationic antimicrobial peptide. Notice the 
segregation of cationic and hydrophobic residues along the peptide. Adapted from Zasloff, M. 
Proc. Natl. Acad. Sci. U.S.A., 1987, 84, 5449-5453.
14
 
Unlike conventional antibiotics, AMPs are considered to exert their bactericidal effect by 
causing cell membrane damage and leakage of cellular components, ultimately triggering 
bacterial cell death. Further contrasting with conventional antibiotics, the antimicrobial 
mechanisms of AMPs do not involve a specific enzyme or binding site. Several models for the 
membrane disruption mechanism of AMPs have been proposed in the field; membrane defects 
induced by peptides include the formation of pores, phase separation, and promotion of non-
lamellar lipid structure or disruption of the membrane bilayer (Figure 1-3).
15
  
 
Figure 1-3. Proposed mechanisms of membrane disruption exerted by antimicrobial peptides. 
The proposed mechanisms include solubilization of membranes due micellization of lipids with 
peptides, the formation of pores lined with peptides and lipids (toroidal model) or pores lined 
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with just peptides (barrel-stave model), and the accumulation of peptides followed by non-
specific membrane disruption (carpet model). The peptides may ultimately cause translocation of 
the AMPs through the membrane into the bacterial cell (cytoplasm) and target intracellular 
components.  
 
AMPs generally consist of 10-50 amino acid residues, and AMPs are classified in 
different groups depending on amino acid composition, size, and conformation.
16,17
 In particular, 
one of the AMP classes extensively investigated in the field is α-helical peptides. α-helical 
AMPs are random coils in solution, but form α-helices upon binding to the bacterial membrane. 
This is followed by membrane disruption and bacterial cell death. The cationic groups on AMPs 
facilitate the preferential binding of AMPs to bacterial cell surfaces which have higher net 
negative charges than human cells. This leads to the selective activity of AMPs to bacteria over 
human cells, resulting in their low toxicity to human cells. However, AMPs and synthetic 
derivatives are not effective in physiological conditions due to enzymatic degradation as well as 
the interference of serum salts and proteins. In addition, the high manufacturing cost prevents the 
translation of AMPs to therapeutic agents. These limitations have led many laboratories to 
develop synthetic mimics of antimicrobial peptides.
18,
 
19,
 
20,
 
21
  
Antimicrobial Polymers 
Peptide-mimetics such as β-amino acids were made to emulate the helical conformation of 
natural AMPs. These peptide backbones are stable in physiological conditions and exert potent 
antimicrobial activity. These peptidomimetics have defined structures and sequences, which are 
advantageous for studies clarifying the relationship between structure and antimicrobial activity 
as well as elucidating their antimicrobial mechanisms. However, these compounds also suffer 
from labor-intensive preparation and difficulties in large scale production.  
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The emerging idea is to design random copolymers with cationic and hydrophobic groups 
which have no defined sequence and molecular size.  Based on this concept, polymethacrylates,
22
 
nylon-3 derived copolymers,
23
 
24
 and poly(norbornene)s 
25
 
26
 have been synthesized 
encompassing the key characteristics of AMPs (Figure 1-4).  Our laboratory has previously 
demonstrated the antimicrobial activity of cationic amphiphilic methacrylate random copolymers 
which act by disrupting bacterial cell membranes, mimicking the mode of action of AMPs.
27
  
These polymers have shown potent activity against a broad spectrum of bacteria and a low 
propensity for resistance development,
28
 which are the hallmarks of AMPs.  Our laboratory 
demonstrated that the polymers form a global amphiphilic conformation in bacterial membranes 
in which the cationic and hydrophobic side chains were segregated onto different sides of the 
polymer backbone (Figure 1-5). The results suggest that the random copolymers adopt 
segregated amphiphilic conformations despite their lack of defined intrinsic secondary structures. 
With the conclusion that random copolymers can exert antimicrobial effects, the design of 
antimicrobial polymers has been extended to a diverse group of polymers and macromolecular 
structures.
29
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Figure 1-4. Representative antimicrobial Polymers. 
 
 
Figure 1-5. Segregated amphiphilic conformation of amphiphilic polymers in bacterial 
membranes. The effect of the spacer arms on the conformation of polymer chain (left) upon 
binding to a bacterial membrane. In molecular dynamics simulations, the polymer backbone 
adopted an extended chain conformation, parallel to the membrane surface (right). A facially 
amphiphilic conformation at the membrane surface was observed, with the primary ammonium 
groups (red) localized at the lipid phosphate region and the nonpolar side chains of EMA 
comonomers (blue) buried in the hydrophobic membrane environment. Adapted from Palermo, 
E.F. et al. Biomacromolecules, 2012, 13, 1632 – 1641.27 
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Challenge: Antimicrobial Polymers with Cell-specificity 
Previously developed antimicrobial copolymers exhibit a broad spectrum of activity, which 
would be useful to eliminate infectious pathogens. However, this non-selective activity may 
negatively impact commensal bacterial flora, especially when used for long-term treatment. It 
would be ideal to develop antimicrobial polymers with cell-selectivity or specificity to bacterial 
strains which can avoid side effects to commensal flora. Antimicrobial polymers with activity to 
specific bacteria will complement the treatment of infections by already developed broad-
spectrum antimicrobial polymers. However, it has been difficult to develop cell-selective 
antimicrobial polymers as new modes of action, which is likely to require targeting of specific 
bacterial components.  
To that end, we have previously demonstrated that conventional cationic polymers 
unmodified branched poly(ethylene imine)s (BPEIs) showed potent antimicrobial activity against 
S. aureus, but did not show any significant activity against E. coli (Figure 1-6). The BPEIs are 
not hemolytic against human red blood cells (RBCs).
30
 Furthermore, the BPEIs do not cause 
membrane permeabilization, indicating that membrane disruption is not the primary mechanism 
of antimicrobial action.
30
 As most amphiphilic antimicrobial peptides and polymers exert their 
activity through membrane disruption, we were motivated to examine how the polymer’s 
structure and chemical composition provided for a different mode of action and bacterial strain 
selectivity. 
 8 
 
 
Figure 1-6. Antimicrobial activity of PEIs. (A) Demonstrates the structural differences between 
BPEI and LPEI. (B) Examines the MIC and HC50 of the polymers. Notice that the BPEIs are 
selective for S. aureus over E. coli and RBCs while the LPEIs are not selective. (C) 
Demonstrates the ability to depolarize S. aureus membranes. LPEI is a membrane disrupter 
similar to melittin, while BPEI does not appear to cause membrane disruption. Data from 
Gibney, K. et al. Macromol. Biosci., 2012, 12, 1279-89.
30
 Figure adapted from Takahashi, H. et 
al, Macromol. Biosci., 2013, 13, 1285-99.
31
 
 
In the literature, other cationic synthetic oligomers and polymers, such as polynorbornenes
26,
 
32
 and oligo-lysins,
33
 have shown selective activity against S. aureus (Figure 1-7).  Similarly, 
cationic natural polysaccharide chitosan showed potent antimicrobial activity against S. aureus 
without inducing significant membrane disruption.
34
 The authors speculate that chitosan may act 
in the cell wall of S. aureus, likely interacting with teichoic acids, and trigger cellular events 
which result in chitosan’s anti-S. aureus activity. While these cationic polymers have 
distinctively different chemical structures, the common cationic groups are likely to play a 
pivotal role in their antimicrobial action and selective activity against S. aureus.
27 
Natural 
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cationic AMPs have been considered to kill bacteria by disrupting bacterial cell membranes. 
However, recent studies indicate that AMPs also exert their antimicrobial effects by binding to 
multiple targets of cell walls, rather than only causing membrane disruption.
11
 These cationic 
polymers may also act in the bacterial cell wall, displaying selective activity against S. aureus 
over other bacteria. The polymers will serve as a simple model to dissect the mode of action of 
antimicrobial polymers and peptides. 
 
Figure 1-7. Cationic polymers with anti-S. aureus activity. 
 
With this in mind, we are interested in the development of cell-selective antimicrobial 
polymers utilizing the mechanism associated with cationic functionality. In particular, we are 
interested in anti-S. aureus agents because S. aureus is a virulent pathogen which causes serious 
infections in the community and in hospitals.  We hypothesize that cationic polymers would be a 
new synthetic platform for potent and selective anti-S. aureus agents. To that end, this 
dissertation focuses on the development of cationic methacrylate homopolymers for potent and 
 10 
 
selective S. aureus agents. Chapter 2 will examine the bacterial-strain specificity of cationic 
methacrylate homopolymers as well as their suitability for in vivo treatment of S. aureus 
infections. Chapter 3 discusses the effect of cationic ammonium structures on their activity and 
their antimicrobial mechanism, focusing on the electrostatic interaction between the cationic 
polymers and the anionic bacterial cell wall. Chapter 4 examines the antimicrobial mechanism of 
amphiphilic methacrylate polymers and cationic homopolymers in relation to pore formation in 
bacterial cell membranes and osmotic lysis. Chapter 5 concludes this dissertation and discusses 
future directions and challenges.   
 11 
 
Chapter 2 : Assessment of in vivo Activity of Methacrylate Homopolymers for Treatment 
of Staphylococcus aureus Nasal Colonization 
 
The work presented in this Chapter is published in Laura M. Thoma, Blaise R. Boles, and 
Kenichi Kuroda, “Cationic Methacrylate Polymers as Topical Antimicrobial Agents against 
Staphylococcus aureus Nasal Colonization”, Biomacromolecules, 2014. DOI: 
10.1021/bm500557d 
 
Introduction 
Synthetic polymers have been widely investigated as a new molecular platform to create 
antimicrobial agents which are active against drug-resistant bacteria.
18
 
19
 
20
 
21
 The Kuroda lab has 
demonstrated the antimicrobial activity of cationic amphiphilic methacrylate random copolymers 
which act by disrupting bacterial cell membranes, mimicking the mode of action of naturally 
occurring antimicrobial peptides.
27
 While these antimicrobial copolymers are potential 
candidates for therapeutic treatment of antibiotic-resistant bacterial infections, they exhibit a 
broad spectrum of activity, which may negatively impact commensal bacterial flora during long-
term treatment. It would be ideal to develop antimicrobial polymers with cell-selectivity or 
specificity to bacterial strains which can avoid side effects to commensal flora.  
 Conventional cationic polymers unmodified branched poly(ethylene imine)s (BPEIs) 
have shown potent antimicrobials against S. aureus, but do not show any significant activity 
 12 
 
against E. coli nor hemolytic activity against human red blood cells. Furthermore, BPEIs do not 
cause significant S. aureus membrane permeabilization, indicating that membrane disruption is 
not the primary antimicrobial mechanism of BPEIs. Cationic natural polysaccharide chitosan 
likewise showed potent antimicrobial activity against S. aureus without inducing significant 
membrane disruption.
34
 This contrasts sharply with the antimicrobial action of membrane 
disruption by AMPs.  
 Given the fact that several cationic polymers with diverse structures are potent and 
selectively active against S. aureus, cationic functionality seem to be vital to the antimicrobial 
mechanism of the polymers against S. aureus. Accordingly, we hypothesize that cationic 
functionality in polymeric structures is the key component for antimicrobial polymers with potent 
and selective activity towards S. aureus.   To test this hypothesis, we used a methacrylate 
polymer as our model, as a methacrylate platform has been used for our previous research on 
broad-spectrum antimicrobial polymers. The living/controlled polymerization of methacrylate 
monomers allows for precise control of the number of cationic groups, facilitating our 
investigation on the activity-structure relationship. In this study, we investigate the in vitro and in 
vivo antimicrobial activity of cationic synthetic polymers as a potential cell-selective 
antimicrobial agent against S. aureus. We are particularly interested in anti-S. aureus agents 
because S. aureus is one of the most common causes of nosocomial and community-acquired 
infections.
35
 
36
 As cationic functionality appears to be an essential characteristic for S. aureus 
specific activity of antimicrobial polymers, we have designed a series of ammonium ethyl 
methacrylate homopolymers (AEMPs) with varying numbers of primary ammonium groups in 
the side chains. This structure contrasts with previously synthesized random copolymers in the 
Kuroda lab which contain both cationic and hydrophobic side chains and exert their 
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antimicrobial effect by disrupting bacterial cell membranes. This series of AEMPs serves as a 
simple model to investigate why the cationic polymers display selective activity to S. aureus and 
to determine if this is a previously uncharacterized mode of antimicrobial action of polymers.  
The purposes of this study are to evaluate the in vitro efficacy of AEMPs as anti-S. 
aureus agents as well as assess the feasibility and effectiveness of these AEMPs for the treatment 
of S. aureus nasal colonization. We particularly targeted the treatment of S. aureus in a nasal 
colonization as nasal passages have proven to be a prime environment for S. aureus colonization 
and play an important role in S. aureus infection.
37, 38
 In this study, the spectrum of activity and 
bactericidal kinetics of the AEMPs will be examined. To assess the activity of AEMPs in 
physiological conditions, their antimicrobial activity in the presence of serum was also 
determined. To evaluate the cytotoxicity of AEMPs, cell viability of mammalian cells HEp-2 and 
COS-7 was determined in the presence of AEMPs using an XTT assay. The propensity for 
resistance development in S. aureus was also evaluated by exposing the bacteria to an AEMP at 
a sub-inhibitory concentration. Finally, the AEMPs were tested for their in vivo activity against a 
S. aureus nasal colonization in a cotton rat model. 
Polymer Synthesis and Characterization 
Boc-protected amino ethyl methacrylate homopolymers (Boc-P series) were prepared by 
reversible addition-fragmentation chain-transfer (RAFT) polymerization of Boc-protected 
aminoethylmethacrylate (AEMA) using 2-cyanoprop-2-yl ethyl trithiocarbonate (CPETC) as a 
chain transfer agent (Figure 2-1). The protection of amine groups facilitates the polymer 
synthesis in organic solvents as well as avoids undesirable aminolysis of the RAFT agent and 
intermolecular amide formation with the ester groups in the monomer. The polymerization 
proceeded at 80°C and quenched by cooling in a dry ice/ ethanol bath after 48 hours. 
 1
H NMR 
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spectra of the crude polymerization mixture indicated at least a 96% conversion of monomer for 
each polymerization. The resulting boc-protected polymers were purified by precipitation into 
hexane. 
 
Figure 2-1. Synthesis of ammonium ethyl methacrylate homopolymers (AEMPs). 
 
GPC analysis of these Boc-protected AEMPs indicated that the polydispersity index 
(Mw/Mn) is ~1.3 (Figure 2-2, Table 2-1). The degree of polymerization (DP) was determined by 
comparing the integrated intensities of the 
1
H NMR resonances from the terminal RAFT agent 
group relative to the monomer side chain (Figure 2-3). In order to examine the effect of 
molecular weight (MW) on antimicrobial activity and cytotoxicity, Boc-protected AEMPs (Boc-
P) were synthesized with different DPs ranging from 9.9 to 19 by varying the ratio of RAFT 
agent to monomers. The Boc-groups of the polymers were removed by treating the polymers 
with trifluoroacetic acid (TFA) to give AEMPs with primary ammonium groups, indicated by the 
disappearance of the peak at 1.5 ppm in the NMR spectrum (Figure 2-3, Appendix B). The DP 
values of deprotected polymers (P series) were in the range of 7.7 to 12, which represents the 
average number of ammonium groups in a polymer. The integrated intensities of the methyl 
groups at the α-end (j) slightly decreased from 3.8 to 2.6 for P7.7, for example, relative to the 6 
protons of methyl groups at the ω-end after the deprotection procedure (Appendix B). This could 
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be attributed to the partial decomposition of the trithioester end groups due to low stability of the 
RAFT agent CPETC under the acidic condition (Appendix C). Because of the decomposition of 
the RAFT agent, the DPs are calculated based on the signals from the α-terminal group. 
Accordingly, the AEMPs will be identified as Px where X is the DP of polymers.  
 
Figure 2-2. GPC Trace of Boc-protected polymers (Waters GPC, RI Detector, THF eluent). 
 
Figure 2-3. 
1
H NMR spectrum of Boc-P9.9 (400 MHz, DMSO-d6). 
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Table 2-1. Synthesis and Characterization of Boc-protected AEMPs. 
Boc-protected Polymer  Deprotected Polymer 
Boc-P 
CPETC
a
 
(%) 
Conv.
b
 
(%) 
Mn, 
GPC
C 
Mw, 
GPC
c Ð
d 
DP
e
 
Mn 
NMR
f
 
 P DP
e 
Mn, NMR
f,g 
Boc-P9.9 22 97 3,300 4,300 1.32 9.9 2,500  P7.7 7.7 
1,200 
(2,100) 
Boc-P11 10 96 5,100 6,700 1.31 11 2,800  P10 10 
1,600 
(2,700) 
Boc-P19
 
3 97 9,800 13,000 1.35 19 4,600  P12 12 
1,800 
(3,200) 
 
a) Mole percentage of CPETC relative to the total amount of monomer in polymerization.  
b) Monomer conversion was determined by comparing the integrations of peaks from vinyl groups 
and monomer side chains in 
1
H NMR spectra.  
c) The number and weight average molecular weight (Mn and Mw) were determined by GPC using 
THF. The molecular weight calibration was based on poly(methyl methacrylate) standards.  
d) Polydispersity index is calculated as Mw/ Mn using Mw and Mn values determined by GPC. 
e) The degree of polymerization (DP) was determined by comparing the integrated intensity of the 
1H NMR resonances from the methyl groups of the α- and ω- terminal RAFT agent group (I and 
j) relative to the side chain (c). 
f) The number-average molecular weights (Mn) were calculated using DP and the molecular 
weights of monomer and CPETC based on the chemical structure of polymers.  
g) The number-average molecular weight (Mn) of deprotected polymers without trifluoroacetate. Mn 
of polymers including trifluoracetate is presented in parenthesis. 
 
 
Antimicrobial Activity 
The AEMPs were tested for their antimicrobial activity against a panel of clinically 
relevant bacterial pathogens. The antimicrobial activity of the AEMPs was quantified as the 
minimum inhibitory concentration (MIC) in which bacterial growth is completely inhibited after 
an 18 hour incubation (Table 2-2, Figure 2-4). The MIC was determined using a turbidity-based 
microdilution method.
39
  In general, the MIC values of AEMPs against Gram-positive bacteria 
tested in this study are smaller than those against Gram-negative bacteria. This indicates that the 
AEMPs were more effective at inhibiting the growth of Gram-positive bacteria when compared 
to the Gram-negative bacteria tested. The AEMPs are also active against community-acquired 
methicillin-resistant S. aureus (CA-MRSA), with the similar MIC values of AEMPs against 
susceptible S. aureus strain.  
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Table 2-2. The antimicrobial spectrum of AEMPs and antibiotics. 
Bacteria Gram 
MIC
a
 (μg/mL) (or μM) 
P7.7 P10 P12 Norfloxacin Mupirocin Vancomycin 
S. aureus 
ATCC 25923 
+ 94 (45) 73 (27) 
63 
(20) 
1.0 (3.1) 0.25 (0.5) 1.3 (0.9) 
S. aureus 
BB2146 
+ 63 (30) 63 (23) 
42 
(13) 
1.1 (3.3) 0.2 (0.4) n.d. 
S. aureus LAC 
(CA-MRSA)
b
 
+ 125 (60) 83 (31) 
63 
(20) 
>8 (>25) 0.25 (0.5) 1.3 (0.9) 
S. saprohyticus + 16 (7.4) 16 (5.8) 
16 
(5) 
0.83 (2.6) 0.13 (0.2) 1.3 (0.9) 
B. subtilis + 83 (40) 63 (23) 
63 
(20) 
1.0 (3.1) >8 (>16) 1.8 (1.3) 
E. faecalis + 156 (74) 94 (34) 
78 
(24) 
1.5 (4.7) n.d. 1.8 (1.3) 
E. coli - 
>1000 
(>476) 
1000 
(370) 
313 
(98) 
n.d. >40 (>80) >40 (>28) 
A. baumannii - 417 (198) 670 (247) 
250 
(78) 
1.3 (4.2) >8 (>16) >8 (>5.5) 
P. aeruginosa - 
1000 
(476) 
50 (185) 
250 
(78) 
0.83 (2.6) >8 (>16) >8 (>5.5) 
a) The MIC in μM is presented in parenthesis, using MW with trifluoroacetate  
b) Community-associated methicillin-resistant S. aureus 
 
 
Figure 2-4. Minimum inhibitory concentrations of AEMPs for selected Gram-positive and 
Gram-negative bacteria. 
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The molecular weight of AEMPs did not appear to have a large influence on an AEMP’s 
activity against any of the Gram-positive bacterial strains tested as the MICs for all AEMPs 
tested for a particular bacterium are within a two-fold dilution. This result suggests that 
increasing molecular weight or the number of cationic groups in the AEMPs has little impact on 
MIC over the molecular weight range tested here. On the other hand, the MIC values of AEMPs 
against E. coli and P. aeruginosa decreased as the molecular weight of AEMPs increased, 
indicating the AEMPs with higher molecular weights are more active against these bacteria. 
However, the MIC values of AEMPs against A. baumannii do not appear to depend on the 
molecular weight of AEMPs. The general trend of AEMPs for lower activity towards Gram-
negative bacteria may be, at least in part, due to the inability of AEMPs to penetrate the outer 
membrane of Gram-negative bacteria, preventing AEMP access to the cell wall and cytoplasmic 
membranes, although the antimicrobial target of AEMPs in bacteria is not clear at this point.  
Membrane Depolarization Assay 
We have previously demonstrated that conventional cationic polymers of unmodified 
branched poly(ethylene imine)s (BPEIs) showed potent antimicrobial activity against S. aureus 
without causing significant membrane permeabilization, indicating that membrane disruption is 
not likely the primary mechanism of antimicrobial action.
30
 To elucidate the antimicrobial 
mechanism and bacterial targets of AEMPs, we attempted to determine membrane 
permeabilization by the AEMPs using a membrane-potential sensitive fluorophore DiSC3(5).
33
 
40
 
This fluorophore binds to intact S. aureus cytoplasmic membranes and undergoes self-
quenching. When the membrane is permeabilized through interaction with the polymers, the self-
quenching of DiSC3(5) is alleviated, and the fluorescence is recovered. As a control, the changes 
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in fluorescence intensity of DiSC3(5) and polymer mixtures in the absence of bacteria were 
determined.  
 
Figure 2-5. Fluorescence intensity of DiSC3(5) in the presence of AEMP and LPEI. The 
fluorescence intensity was determined by monitoring the absorbance of the dye mixed with 
polymers in the absence of S. aureus. Dye was added into PBS buffer (final concentration 0.5 
μM) and mixed with polymers at their MIC concentrations. A) Shows the dye alone, and mixed 
separately with LPEI and P7.7 at their MICs. B) Shows the dye mixed with P7.7 at various 
concentrations. Open arrows indicate the point of polymer addition.  
 
Figure 2-5 shows the change in absorbance of the dye mixed with polymers in the 
absence of S. aureus. Both LPEI and P7.7 caused a decrease in fluorescence at a much faster rate 
than the dye self-quenches in the absence of bacteria (Figure 2-5A). As the concentration of P7.7 
increased, the rate of fluorescence quenching also increased (Figure 2-5B). It is likely that the 
polymer binds to the dye, and the interaction between the polymer and the dye causes quenching 
of fluorescence from the dye, although the molecular mechanism is not clear at this point.  
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Figure 2-6. S. aureus membrane depolarization by LPEI and AEMP. 
 
 Figure 2-6 shows the change in fluorescence induced by the polymer mixtures in the 
presence of S. aureus. Figure 2-6A demonstrates the change in fluorescence in the presence of 
LPEI, with results similar to what we have previously demonstrated.
30
 LPEI causes membrane 
depolarization, as demonstrated by the increase in fluorescence from DiSC3(5) after the 
polymer’s addition to S. aureus solution. Figure 2-6B-D demonstrates the change in fluorescence 
from DiSC3(5) bound to S. aureus upon the addition of various concentrations of P7.7. Only a 
slight change in fluorescence was observed at polymer concentrations 1x, 2x, or 5x the MIC of 
P7.7. However, as the polymer reduced the fluorescence of DiSC3(5) in solution (Figure 2-5), the 
results could be due to fluorescence quenching by the polymer rather than the inability of the 
polymer to cause membrane depolarization. Therefore, this approach cannot determine if the lack 
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of substantial change in fluorescence upon introduction of P7.7 shows that P7.7 doesn’t cause 
membrane depolarization or if it is a result of the fluorescence quenching by the polymer. In 
addition, closed arrows mark the addition of LPEI, a known membrane depolarizer, for P7.7 at the 
MIC and at 5x the MIC. After the addition of LPEI for P7.7 at the MIC, the fluorescence 
increased, indicating that membrane depolarization does occur. However after the addition of 
LPEI to P7.7 at 5x the MIC there is no change in the fluorescence. This is likely either because 
the high concentration of P7.7 quenches the fluorescence caused by LPEI or P7.7 in the cell wall 
prevents membrane depolarization, possibly by inhibiting the diffusion of LPEI through the cell 
wall to the cell membrane. It cannot be ruled out that P7.7 binds to LPEI, which may sequester 
LPEI from solution. In conclusion, the membrane depolarization assay using DiSC3(5) does not 
provide quantitative results to determine the ability of P7.7 to cause membrane depolarization in 
S. aureus due to the strong quenching of fluorescence from DiSC3(5) by the polymer. It should 
be noted that LPEI did not cause significant quenching of DiSC3(5),
30
 and we here provide a 
caution to the use of this assay for cationic polymers.  
Cell Leakage Assay 
In addition to the fluorescence assay, we also performed a cell leakage assay to determine 
membrane damage by the AEMPs. E. coli and S. aureus cells were incubated with P7.7 for 2 
hours and the cells are removed by centrifugation. The absorbance of cell-free supernatant at 260 
nm was measured to determine if any UV-absorbing compounds leaked from S. aureus cells as a 
result of any damage to membrane integrity.  
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Table 2-3. Absorbance of assay solutions. 
 E. coli S. aureus 
Starting OD600 0.250 0.250 
OD600 after centrifugation 
PBS 0.0299 0.0288 
PBS, bacteria 0.0321 0.0255 
PBS, bacteria, CTAB 0.0278 0.0276 
PBS, bacteria, Lysostaphin 0.0271 0.0264 
PBS, bacteria, Melittin 0.0309 0.0289 
PBS, bacteria, P7.7 0.0281 0.0277 
 
CTAB, lysostaphin, melittin, and P7.7 were tested for their ability to cause leakage of 
cellular components from E. coli or S. aureus. PBS buffer without any compounds was used as a 
control. All test compounds were used at a final concentration of at least 3x their MIC in the 
representative bacteria. After 2 hours, the assay solution was centrifuged at 14,000 rpm for 10 
minutes. The OD600 values of assay solutions are close to PBS, indicating that the supernatant 
was cell-free after centrifugation (Table 2-3). The absorbance of the supernatant was measured at 
260 nm to detect UV-absorbing cellular components. As a background, the absorbance of test 
compounds in PBS without bacteria was determined, and subtracted from the absorbance reading 
in the presence of bacteria at 260 nm. The corrected absorbance for E. coli and S. aureus are 
show in Figure 2-7. 
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Figure 2-7. Detection of UV-absorbing cellular components. 
 
PBS was used as a negative control, as it should cause no leakage of cellular components 
from the bacterial membrane, CTAB (a cationic surfactant) and melittin (lytic peptide) were used 
for comparison. Lysostaphin, an endopeptidase capable of cleaving the crosslinking pentaglycin 
bridges of Staphylococci for cell lysis, was used as a positive control for 100% leakage for S. 
aureus. P7.7 showed a large increase in absorbance at 260 nm for both bacteria after 2 hour 
treatment. It appears that P7.7 causes strong membrane permeabilization. However, the 
absorbance caused by P7.7 is significantly higher than the absorbance for lysostaphin and 
melittin, controls that we expected to give 100% lysis of bacterial cells and subsequent protein 
leakage. Therefore, because of the amphiphilic nature of the polymer, P7.7 is likely to bind to 
cellular components such as proteins and lipids, which may cause formation of small aggregates. 
The small aggregates may result in the apparent increase in the UV absorbance due to light 
scattering. The polymer aggregates may also change the environment of UV-sensitive functional 
groups of proteins, increasing the absorbance. In conclusion, the membrane permeabilization 
assay monitoring UV-absorbing cellular components does not provide quantitative results to 
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determine the ability of P7.7 to cause membrane permeabilization in bacteria due to the increased 
absorbance, which is likely to reflect the aggregation of cellular components with polymer.  
Antimicrobial Activity in the Presence of Serum 
 To evaluate the activity of AEMPs in physiological conditions, the MIC values of 
AEMPs were determined in the presence of fetal bovine serum (FBS). It has been reported that 
the activity of antimicrobial peptides is reduced in the presence of serum because the serum salts 
curtain the electrostatic binding of cationic peptides to anionic bacterial surfaces and serum 
proteins such as albumin non-specifically bind to peptides.
41,42 
Therefore, the activity of AEMPs 
could also be mitigated in the presence of serum.  
AEMP activity was determined in 50% (v/v) FBS in MH broth (MHB). MHB 
components could non-specifically bind to the polymers, reducing the polymer activity. The 
reduction of these antagonizing factors in MHB by dilution with PBS buffer would increase their 
antimicrobial activity (decrease MIC values). To take this dilution effect into account, we used 
50% PBS buffer in MHB as a control. 
 
Table 2-4. The antimicrobial activity of AEMPs in the presence of fetal bovine serum. 
Bacteria Condition 
MIC (μg/mL) 
P7.7 P10 P12 CTAB Mupirocin Norfloxacin 
E. coli 
MHB >1000 670 250 35 n.d. n.d. 
50% PBS >1000 670 104 35 n.d. n.d. 
50% FBS >1000 >1000 >1000 >63 n.d. n.d. 
S. aureus 
ATCC 
25923 
MHB 130 63 63 0.98 0.5 1.3 
50% PBS 63 31 16 0.98 0.5 1.0 
50% FBS 20 5.9 6.8 > 7.8 > 4.0 2.0 
S. aureus 
BB 2146 
MHB 83 63 42 0.81 0.33 1.0 
50% PBS 31 16 16 0.41 0.25 0.67 
50% FBS 3.9 2.0 2.0 6.5 >4.0 1.0 
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Figure 2-8. The effect of FBS on the activity of AEMPs and mupirocin against S. aureus strains. 
 
Against E. coli, all of the polymers did not show any activity in the presence of FBS 
(MIC > 1000 µg/mL), while the high MW polymers P10 and P12 are active towards E. coli in the 
absence of FBS (Table 2-4). The MIC of cationic surfactant CTAB also increased in 50% FBS, 
indicating that serum components generally reduce the activity of cationic polymers, AEMPs, 
and surfactants.  
Interestingly, the MICs of AEMPs for S. aureus decrease significantly in in the presence 
of FBS when compared to those in MHB. For example, P7.7, which is used for the in vivo testing 
described later, had an MIC of 125 μg/mL in MHB and a MIC of 19.5 μg/mL in FBS, giving 6-
fold reduction in MIC (Figure 2-8).  The MIC of P7.7 showed a 2-fold reduction in PBS/MHB, 
indicating that the MIC reduction of P7.7 in FBS is not just due to the effect of the dilution of 
MHB described above.  The MIC of AEMPs with higher molecular weights also decreased in the 
presence of serum to give MICs of 5.9 and 6.8 µg/mL for P10 and P12, respectively, which is 
about a 10-fold reduction in their MIC values as compared to those in MHB (Table 2-4). The 
MIC values of AEMPs in 50% FBS are 6-20 µg/mL (Table 2-4), which are comparable to those 
of potent antimicrobial polymers reported in literature
43
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47
  although the literature values 
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were generally determined in the absence of serum. In addition, caution must be taken when 
comparing MIC values between research groups as many groups use different assay protocols, 
and the MIC values depend on multiple assay conditions including bacterial strains, assay plates, 
and broth media. The MICs of  AEMPs for S. aureus strain BB2146, the in vivo strain used later, 
are 2 – 4 µg/mL, indicating that the polymers are highly active against this strain of  S. aureus. 
The MIC values of the surfactant CTAB and the antibiotic mupirocin, an RNA duplication 
inhibitor
48
 which is widely used in the topical treatment of skin/wound infections, significantly 
increased in 50% FBS, indicating that FBS does not generally increase S. aureus susceptibility to 
antimicrobials. However, the mechanism of potent activity of AEMPs in FBS is not clear at this 
point. It should be noted that the decrease in MIC of AEMPs for S. aureus was observed for 
different batches of AEMPs with different lots of FBS, suggesting that the results presented in 
this report are not batch/lot specific.  In summary, the AEMPs showed potent activity against S. 
aureus in the presence of FBS, which contrasts with the activity reduction for CTAB and 
antibiotics. These results demonstrate that these AEMPs have potential for potent activity against 
S. aureus infections in physiological conditions.  
Bactericidal Kinetics 
We examined the bactericidal activity exerted by the AEMPs against S. aureus ATCC 
25923 and their time dependence to assess the rate of killing. Accordingly, we monitored the 
number of viable S. aureus cells in a colony-forming unit (cfu) as a function of exposure time to 
the AEMPs at concentrations of twice their respective MICs. We used the conventional 
antibiotics mupirocin and norfloxacin (DNA gyrase and topoisomerase IV inhibitor)
49
 
50
 for 
comparison.  
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Figure 2-9. Bactericidal kinetics of AEMPs and antibiotics mupirocin and norfloxacin at 2 times 
MIC. The detection limit is 10 cfu/mL due to the dilution factor in this assay. 
 
At two times the MIC the antibiotic mupirocin caused less than one log reduction in the 
number of viable S. aureus (Figure 2-9), indicating that mupirocin is rather bacteriostatic under 
this condition, which is in agreement with literature.
51
 Norfloxacin did not cause any change in 
the number of viable S. aureus cells while the bacteria were in the lag phase of growth (0 – 40 
min.), but after 40 minutes the number of viable cells started to decrease, with a two log 
reduction after 190 minutes. After 18 hrs, the bacteria treated with norfloxacin grew back slightly 
which is in agreement with literature.
52
  
In contrast to the antibiotics tested, the AEMPs showed killing of S. aureus with 
relatively higher killing rates. All three polymers are bactericidal at 2 times their MICs, and 
caused four-log reductions in the number of viable bacteria (99.99% killing) within 360 minutes. 
The highest MW polymer, P12, caused a three-log reduction in the number of viable cells (99.9% 
killing) after 60 minutes, while P10 and P7.7 needed at least twice as much time, with 130 and 210 
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minutes respectively, for the same three-log reduction. This demonstrates that for AEMPs the 
rate of killing increased as the molecular weight of polymers increased.  
After 18 hours, the bacteria incubated with the lower MW polymers P7.7 and P10 grew 
back to give a two-fold (99%) or three-fold (99.9%) reduction in the number of initial bacteria. 
This indicates that some population of bacteria may be resistant to the antimicrobial action of the 
AEMPs and are still viable. The development of S. aureus resistance to the polymer will be 
discussed in detail below.  
Resistance Development 
To assess the potential emergence of antibacterial resistance to AEMPs, S. aureus was 
exposed to sub inhibitory concentrations (1/2 MIC) of antimicrobial agents during successive 
subcultures. We used P7.7 as a model compound and two conventional antibiotics norfloxacin and 
mupirocin as positive controls, as development of antibiotic resistance in S. aureus to these 
antibiotics has been previously reported.
53
 
54
 
The MIC values of P7.7 and the antibiotics against S. aureus were determined for each 
passage over 14 successive subcultures (Figure 2-10A). The MIC values of norfloxacin started to 
increase on the first passage and continuously increased up to 64 times the starting MIC at the 
11
th
 passage. The MIC of mupirocin began increasing at the 2nd passage and continued 
increasing up to 6 times the original MIC at the 11
th
 passage. On the other hand, the MIC of P7.7 
started to increase at the 4
th
 passage and increased up to 6 times the original MIC after 12 
passages, the same final level of resistance development as mupirocin. 
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Figure 2-10. Propensity of AEMP P7.7 for resistance development in S. aureus. (A) Fold increase 
in MIC against S. aureus as a function of passage. One-sided error bars were presented for 
clarity. (B) Relative increase in MIC after 14 passages. 
 
It has been reported that S. aureus have become resistant to cationic antimicrobial 
peptides by chemically modifying their major cell wall biopolymers, anionic teichoic acids.
55
 
The bacteria modify the cell walls through alanyl esterification of the teichoic acids. This 
reduces the net anionic charge in the S. aureus cell wall,
56
 
57
 decreasing the electrostatic binding 
of cationic polymers to the bacterial cell surface. The same resistance mechanism would also 
reduce the electrostatic binding of cationic polymers to S. aureus, resulting in lower AEMP 
activity or an increase in MIC. While this is a possible resistance mechanism, the antimicrobial 
target of AEMPs in bacteria, and their actions resulting in resistance development, is not clear at 
this point. 
Hemolytic Activity 
 As an initial metric of biocompatibility, the lysis of human red blood cells (hemolysis) 
by AEMPs was measured. The AEMPs showed 1.6% to 7.6% hemolysis at 1000 μg/mL, the 
highest concentration tested (Figure 2-11), indicating that the AEMPs are not potent hemolysins. 
For comparison, under the same assay condition, bee venom toxin melittin causes 100% 
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hemolysis at concentrations as low as 10 μg/mL (data not shown). In corroboration with the 
antimicrobial activity of AEMPs, the AEMPs are antimicrobial against Gram-positive bacteria 
over Gram-negative bacteria, but not hemolytic, indicating the AEMPs are cell-selective to 
Gram-positive bacteria.  
 
Figure 2-11. Hemolytic activity of AEMPs against human red blood cells, with the hemolysis by 
Triton X as 100%. 
Cell Cytotoxicity 
To assess the toxicity profile of AEMPs, the reduction of cell viability of mammalian 
cells exposed to AEMPs (cytotoxicity) was determined. We used human epithelial HEp-2 cells 
for cytotoxicity testing as AEMPs could be used as topical antimicrobials for skin and nasal 
infections. Monkey kidney fibroblast COS-7 cells were also used to test for cytotoxicity in order 
to examine the cell dependence of AEMP cytotoxicity. The cell viability was determined using 
the XTT colorimetric assay.
58
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 In addition to the AEMPs, commercially available polymers 
including neutral non-toxic polyethylene glycol (PEG, MW 2000) as well as branched cationic 
polymer poly(ethylene imine) (BPEI, MW 1800) were used for comparison.  
For both cell lines tested, the cell viability decreased with increasing AEMP and BPEI 
concentrations, eventually reaching 0% (complete cell death) (Figure 2-12). PEG did not show 
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any signification reduction in cell viability for either cell line. For the AEMPs, cell viability 
decreased with increasing polymer concentration, and the cytotoxicity of AEMPs was dependent 
on the molecular weight of the AEMP. The polymer concentration which caused a 50% 
reduction in cell viability after 24 hour incubation with AEMPs was defined as the IC50 value 
(Table 2-5). 
 
Figure 2-12. Cytotoxicity of AEMPs. Cell viability of HEp-2 (A) and COS-7 (B) cells was 
determined after 24 hour incubation with AEMPs. 
Table 2-5. Cytotoxicity of AEMPs to HEp-2 and COS-7 cells. 
Polymer 
IC50 (μg/mL)
a
 
HEp-2 COS-7 
P7.7 250 >1000 
P10 75 270 
P12 20 55 
PEG (MW 2000)  >1000 >1000 
BPEI (MW 1800) 85 175 
a) Concentration for a 50% reduction in cell viability. 
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For HEp-2 cells, the IC50 values decreased as the molecular weight of the AEMPs 
increased, indicating that high molecular weight or more cationic groups of AEMPs cause higher 
cytotoxicity (Figure 2-12A). It has been previously reported that traditional cationic polymers 
such as PEIs and PAMAM dendrimers likely cause cytotoxicity by increasing the permeability 
of the cell membrane of mammalian cells
60
 
61
 
62
 and that membrane permeabilization was 
strongly dependent on the number of cationic charges presented by the polymer and dendrimer 
surfaces.
61
 
62
 The structure-function study on the cytotoxicity of cationic amine-poly(vinyl 
alcohol) polymers demonstrated that the cationic ammonium groups of polymers may bind 
through multiple points to cell membranes, resulting in membrane disruption or 
permeabilization.
63
 These results indicated that cationic functionality in polymer structures may 
have an intrinsic toxicity mechanism against host cells through interactions with cell membranes. 
Similarly, the polycationic AEMPs may also cause cytotoxic effect by permeabilizing cell 
membranes. The high MW AEMPs have higher cationic densities resulting in the higher 
cooperative action of cationic groups for membrane binding and permeability as they are able to 
have multiple-point interaction with lipids. This would result in a higher toxicity (a lower IC50 
value) than their lower molecular weight counterparts. 
For COS-7 cells, all AEMPs reduced cell viability when compared to PEG which showed 
100% COS-7 viability across all concentrations tested (7.8 – 1000 μg/mL, Figure 2-12B). The 
higher MW AEMPs cause a larger reduction in cell viability as P12 was the most cytotoxic (IC50 
= 55 μg/mL) followed by P10 (IC50 = 270 μg/mL) and P7.7 (IC50 > 1000 μg/mL). This difference 
due to molecular weight indicates that more cationic groups on AEMPs cause an increase in 
toxicity to COS-7 cells, identical to the trend shown for HEp-2 cells. As the IC50 values of 
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AEMPs for HEp-2 cells are lower than those for COS-7 cells, it appears that HEp-2 cells are 
more susceptible to the AEMPs than COS-7, although the reason for this is not clear (Table 2-5).  
Selectivity to Bacteria Over Mammalian Cells 
To examine the selective activity of AEMPs to bacterial cells over mammalian cells, we 
determined the IC50/MIC as a selectivity measure (Table 2-6). In general, due to the low activity 
of AEMPs against E. coli (MICs > 1000 µg/mL), the selectivity indices for E. coli are small (< 
0.3) for all polymers, indicating that the AEMPs are not selective to E. coli over mammalian 
cells. On the other hand, the low molecular weight AEMPs P7.7 and P10 showed higher selectivity 
for S. aureus than P12. These data demonstrate that P7.7 and P10 are more selective for S. aureus 
over both HEp-2 and COS-7 cells. The AEMPs P7.7 and P10 showed potent activity against S. 
aureus in the presence of FBS (MIC = 2 - 4 µg/mL for S. aureus BB2146 and 13 µg/mL for S. 
aureus ATCC 25923), indicating that these two AEMPs would be good candidates for in vivo 
applications for treatment of S. aureus infections as demonstrated below. 
Table 2-6. Selectivity of AEMPs to S. aureus over mammalian cells. 
Polymers  HEp-2
 a
 
 
 COS-7
 a
 
 
E. coli ATCC 25923 BB 2146 E. coli ATCC 25923 BB 2146 
P7.7 > 0.3 (< 0.3) 2.0 (13) 4.0 (64)  
- (-)
b
 8.0 (> 51) 16 (> 256) 
P10 0.1 (< 0.1) 1.2 (13) 1.2 (39)  
0.3 (< 0.3) 4.3 (46) 4.3 (139) 
P12 0.1 (< 0.1) 0.3 (3.0) 0.5 (10)  
0.2 (< 0.1) 0.9 (8.1) 1.3 (28) 
a) Selectivity is calculated by IC50/MIC (MHB). The selectivity index for MIC in 50% FBS in MH broth is 
presented in parentheses. b) Not applicable because IC50 > 1000 μg/mL and MIC E. coli > 1000 μg/mL. 
 
In vivo Antimicrobial Activity of AEMPs 
As a preliminary assessment of the in vivo topical treatment of S. aureus infections using 
AEMPs, we choose a cotton rat nasal S. aureus colonization model because of the clinic issues 
associated with nasal S. aureus colonization. The nasal cavity is the primary reservoir for S. 
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aureus, with approximately 30% of the human population being asymptomatically colonized.
64
 
65
 
66
 Patients who are asymptomatically colonized are at significantly higher risk for several 
infections including bacteremia, post-operative infections, and diabetic foot ulcer infections. 
Most nosocomial S. aureus infections are caused by the patient’s own S. aureus cells 67 68 69 and 
the nasal environment serves as a hotbed for drug-resistance development of S. aureus.
70
 
64
 
65
 
66
 
Treatment with the topical antibiotic mupirocin has proven to be effective at reducing nasal 
colonization and the risk of postoperative infection.
66
 
68  
However the appearance of mupirocin 
resistance threatens this nasal eradication strategy.
71 
S. aureus strain BB2146
70
 colonies were allowed to establish in the nasal passage for 3 
days. After 3 days, the rats were given a nasal spray treatment consisting of either polymer (P7.7 
or P10), mupirocin (antibiotic control), or PBS buffer (control). Mupirocin was added at a 
treatment concentration of 400 μg/mL, which is 2000 x MIC (MHB) (800 µM), ast his treatment 
concentration has been demonstrated to eliminate most S. aureus strains from the nose.
72
 P7.7 was 
added at a treatment concentration of 125 μg/mL. This concentration was used for treatment as it 
is higher than the MIC of P7.7 against S. aureus BB2146 (MIC (MHB) = 63 µg/mL, MIC (50% 
FBS) = 3.9 µg/mL), and HEp-2 and COS-7 are tolerant to the polymer (the cell viabilities of > 
90%), giving the maximum polymer concentration for the selective activity to S. aureus over 
mammalian cells. After three days, the animals were sacrificed and the number of S. aureus cells 
in each nasal passage were determined (Figure 2-13). Trial 1 involved 5 animals for P7.7, 3 
animals for mupirocin, and 3 animals for PBS buffer (control). Trial 2 involved 5 animals for 
P10, 5 animals for mupirocin, and 5 animals for PBS buffer. The experiments for P7.7 and P10 
were performed independently and the combined data for these controls (PBS control and 
mupirocin) are presented below (Figure 2-13). All data from these two trials are provided in 
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Appendix D. As mupirocin has widespread use in the S. aureus nasal decolonization,
73
 
74
 
mupirocin provides a benchmark for the efficacy of antimicrobials.  
 
Figure 2-13. In vivo assessment in a cotton rat nasal S. aureus colonization model. *p < 0.001; 
**p < 0.0001. In vivo experiments were performed by Dr. Blaise R. Boles.  
 
Mupirocin and P7.7 reduced the number of viable S. aureus cells when compared to the 
PBS control and the difference in reduction between these two treatments is not statistically 
significant. Therefore, under these test conditions, P7.7 is as effective at reducing the number of 
viable S. aureus cells as mupirocin. It should be noted that the treatment concentration of P7.7 is 
about two times the MIC while mupirocin used a treatment concentration 2000 times the MIC, 
although lower concentrations of mupirocin may be effective.  
AEMP P10 was also tested as a treatment for S. aureus nasal colonization (MIC for S. 
aureus BB2146 = 63 μg/mL in MHB and 2.0 μg/mL in 50% FBS) at the same polymer treatment 
concentration (125 μg/mL) as for the testing of P7.7, although at this concentration the polymer 
indicated the significant cytotoxicity to HEp-2 cells (Figure 2-12A). P10 also showed a significant 
reduction in the number of viable S. aureus cells when compared to the PBS treatment control. 
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As a result of the in vivo tests, AEMPs demonstrate encouraging treatment outcomes of S. aureus 
in a nasal infection.  
 
Conclusions 
In summary, we investigated the in vitro and in vivo antimicrobial activity of cationic 
ammonium ethyl methacrylate polymers (AEMPs) with primary ammonium groups in the side 
chains with varying molecular weights. The AEMPs were active against Gram-positive bacteria 
when compared to Gram-negative bacteria although the polymers did not show a strong 
preference to any specific Gram-positive bacteria. The AEMPs also inhibited methicillin-
resistant S. aureus with similar MIC values against the susceptible strain. The AEMPs also 
showed potent activity against S. aureus in the presence of FBS while their activity against E. 
coli was reduced, suggesting that the AEMPs may be active against S. aureus infections in 
physiological conditions. However, the antimicrobial mechanism of AEMPs and their targets in 
bacteria is not clear at this point. The AEMPs showed bactericidal activity against S. aureus with 
higher rates as compared to other antibiotics. AEMP P7.7 showed similar resistance development 
as mupirocin (6 times original MIC after 14 passages). In a cotton rat nasal infection model, the 
AEMP P7.7 significantly reduced the number of viable S. aureus cells. This AEMP was as 
effective at reducing the number of viable S. aureus cells as mupirocin when compared to the 
control without polymer treatment. These in vivo tests demonstrate the potential of cationic 
methacrylate homopolymers, particularly with primary ammonium groups, for use in the 
treatment of S. aureus infections. However more work is needed to better understand the 
antimicrobial mechanism of these polymers to aid in the design of more potent antimicrobials.   
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The development of antimicrobial polymers have been focused on the design of polymers 
with both cationic and hydrophobic groups in the side chains for the efficient disruption of 
bacteria cell membranes, which mimic the function of natural host-defense antimicrobial 
peptides. However, our study indicates that cationic homopolymer AEMPs without strong 
hydrophobic moieties can exert antimicrobial activity, and interestingly show potent anti-S. 
aureus activity in the presence of serum. Recent studies indicate that naturally occurring 
antimicrobial peptides exert their antimicrobial effects by binding to the multiple targets of cell 
walls, in addition to membrane disruption, which may be one of the components in the 
antimicrobial mechanism of peptides.
75
 The AEMPs will serve as a simple model for the 
antimicrobial mechanism of cationic polymers as well as may capture the modes of action 
associated with cationic functionality in the bacterial cell walls. Although not investigated in this 
study, the antimicrobial activity of AEMPs is likely pH dependent due to the protonation of 
primary amine groups. We have previously demonstrated that chemical structures of ammonium 
groups (primary, tertiary, and quaternary) determine the binding of polymers to bacterial cell 
membranes and antimicrobial activity against E. coli.
76
 
77
 Tuning of cationic functionality of 
polymers would be of interest in the design of pH-responsive antimicrobial polymers as 
previously demonstrated using acidic groups.
78
 Our finding may provide a new design strategy 
for antimicrobial polymers effective in physiological conditions and provide new insight into the 
mode of action of antimicrobial polymers with cell-selective activity.  
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Chapter 3 : Methacrylate Homopolymers as Cell Wall Targeting Antimicrobials 
Introduction 
The previous chapter investigated the antimicrobial activity of aminoethyl methacrylate 
homopolymers (AEMPs). AEMPs showed selective activity to Gram-positive over Gram-
negative bacteria and potent activity against S. aureus in the presence of serum. However we 
were unable to identify if the primary antimicrobial mechanism of the polymers was membrane 
disruption due to limitations in assay conditions or to determine any other underlying mechanism 
or bacterial targets. As other cationic polymers, including BPEIs
30
, oligolysines, and natural 
polysaccharide chitosan
79
 have shown potent S. aureus activity without inducing significant 
membrane disruption. Instead, these polymers may act in the S. aureus cell wall by a previously 
uncharacterized mechanism. Similar in both cationic structure and antimicrobial activity, the 
AEMPs may also employ a similar antimicrobial mechanism that doesn’t rely on the membrane 
disruption common to AMPs.  
In the view of bacterial cell wall as antimicrobial target, Bacteria are surrounded by a 
complex cell envelope that performs a variety of essential functions.
80
 Contrasts between the cell 
wall of Gram-positive and Gram-negative bacterial cells can be seen in Figure 3-1. While the cell 
envelope structure of bacteria varies, all cell envelopes contain layers of peptidoglycan (PG), a 
cross-linked matrix of linear carbohydrate (glycan) chains connected to each other via covalent 
bonds between attached peptides.
81
 This peptidoglycan matrix is essential for survival, and in 
Gram-positive organisms it is densely functionalized with other glycopolymers.  
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Figure 3-1. Comparison of Gram-positive and Gram-negative bacterial membranes. Adapted 
from Vollmer, W. et al. FEMS Microbiol. Rev. 2008, 32, 149-167.
82
 
 
The main glycopolymers in Gram-positive organisms are teichoic acids. Teichoic acids 
describe the cell surface glycopolymers containing phosphodiester-linked polyol repeat units.
83
 
Teichoic acids present in bacterial cells include lipoteichoic acids (LTAs) which are anchored in 
the bacterial membrane via a glycolipid, and wall teichoic acid (WTA) which are covalently 
attached to the peptidoglycan (Figure 3-2).
84,83
 Wall teichoic acids (WTAs) are the most 
abundant glycopolymer in Gram-positive organisms,
84
 constituting up to 60% of the total mass 
of the cell wall.
85,86
 The structure of S. aureus wall teichoic acids can be seen in Figure 3-3. 
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Figure 3-2. Teichoic acid polymers are located within the Gram-positive cell wall. Adapted from 
Brown, S. et al. Annu. Rev. Microbiol., 2013, 67, 313-36.
87
 
 
 
Figure 3-3. S. aureus wall teichoic acids (WTAs) are composed of ribitol-phosphate repeats 
tailored with D-alanines, α-O-GlcNAcs, and β-O-GlcNAcs. Taken from Brown, S. et al, Proc. 
Natl. Acad. Sci. U.S.A., 2012, 109, 18909-18914.
88
 
 
According to the results from the previous chapter and upon examining the cell wall 
structure of S. aureus, we hypothesize that (1) electrostatic binding of cationic polymers to the 
anionic cell wall biopolymers would be the dominant factor in the mechanism of cationic 
methacrylate homopolymers, and (2) therefore, the polymers with quaternary ammonium groups 
would be more efficient in growth inhibition of S. aureus than their counterparts with primary 
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ammonium groups because quaternary ammonium groups are not pH-dependent, providing 
higher charge density at physiological pH than primary ammonium groups. While quaternary 
ammonium compounds have previously demonstrated antimicrobial activity, investigation of 
these compounds usually pairs them with long alkyl chains which aim to disrupt bacterial cell 
membranes.
89
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The purposes of this study are to improve the activity of polymers against S. aureus as 
well as to probe the antimicrobial mechanism of these cationic polymers. In this study we 
prepared a series of cationic methacrylate homopolymers with either primary ammonium or 
quaternary ammonium groups in the side chains. To assess overall antimicrobial activity, the 
spectrum of activity of the polymers was determined. To assess the activity of AEMPs in 
physiological conditions, their antimicrobial activity in the presence of serum was also 
determined. As an initial assessment of their toxicity, the hemolytic activity of AEMPs was 
determined. Finally, to determine the role of electrostatic interaction between the polymers and 
S. aureus in the antimicrobial activity, polymers with primary ammonium or quaternary 
ammonium groups in the side chains were tested for their antimicrobial activity against a S. 
aureus cell wall mutant which has a higher net negative charge in the cell wall than the wild 
type. 
Polymer Synthesis and Characterization 
Synthesis of methacrylate homopolymers with primary ammonium groups.  
Boc-protected amino ethyl methacrylate was prepared as previously described (see 
Appendix A).
27
 Boc-protected polymers were prepared by free-radical polymerization using 
methyl 3-mercaptopropionate (MMP) as the chain transfer agent (Figure 3-4). The ratio of MMP 
to monomer concentration was varied to obtain polymers with a range of degree of 
 42 
 
polymerization (DP). The polymerization proceeded at 65°C for 18 hours. The resulting boc-
protected polymers were purified by precipitation into hexane. The boc-groups of the polymers 
were removed by treating the polymers with trifluoroacetic acid (TFA) to give polymers with 
primary ammonium groups. The polymers with primary ammonium will be identified as Px 
where X is the DP of the polymer as determined by comparing the integrated intensities of the 
1
H 
NMR resonances from the terminal group relative to the monomer side chain.   
 
Figure 3-4. Synthesis of ammonium ethyl methacrylate homopolymers with primary ammonium 
groups. 
 
Figure 3-5. 
1
H NMR spectrum of Polymer with Primary ammonium groups (400 MHz, 
Methanol-d4). 
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Table 3-1. Synthesis and Characterization of Polymers with Primary ammonium groups 
 
MMP (%) 
Boc-Protected Deprotected 
 DP Mn DP Mn
a 
P115 2 43 10,000 115 28,200 (15,100) 
P92 1 60 13,900 92 22,600 (12,100) 
P27 20 16 3,800 27 6,700 (3,600) 
P24 5 21 4,900 24 5,900 (3,200) 
P17 10 16 3,800 17 4,300 (2,300) 
a) The number-average molecular weight (Mn) of deprotected polymers without trifluoroacetate. Mn 
of the polymers including trifluoroacetate are presented in parentheses.  
 
Synthesis of methacrylate homopolymers with quaternary ammonium groups.  
Ethyl methacrylate homopolymers with quaternary ammonium groups were prepared by 
the same method as described above for homopolymers with primary ammonium groups (Figure 
3-6). The resulting polymers were purified by precipitation from methanol into diethyl ether. 
Polymers were then lyophilized to afford homopolymers bearing quaternary ammonium groups 
in the form of chloride salts. The polymers with quaternary ammonium side chains will be 
identified as Qx where X is the DP of the polymer as determined by comparing the integrated 
intensities of the 
1
H NMR resonances from the terminal group relative to the monomer side 
chain
 1
H NMR.  
 
Figure 3-6. Synthesis of ammonium ethyl methacrylate homopolymers with quaternary 
ammonium groups. 
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Figure 3-7. 
1
H NMR spectrum of Polymer with quaternary ammonium groups. 
 
Table 3-2. Synthesis and Characterization of Polymers with Quaternary ammonium groups. 
 MMP (%) DP Mn 
Q37 9.4 37 7,800 
Q32 15 32 6,800 
Q19 5.6 19 4,100 
Q11 15 11 2,400 
Q10 3.7 10 2,200 
Q9 14 9 2,000 
 
Antimicrobial Activity 
 The series of polymers with quaternary ammonium groups (Q-polymers) and the series of 
polymers with primary amine groups (P-polymers) were tested for their antimicrobial activity 
against a panel of clinically relevant bacterial pathogens. The antimicrobial activity of the 
prepared polymers was quantified as the minimum inhibitory concentration (MIC) in which 
bacterial growth is completely inhibited after an 18 hour incubation. The MIC was determined 
using a turbidity based microdilution method. 
39
 Both P-polymers and Q-polymers were more 
effective at inhibiting the growth of S. aureus strains when compared to other bacteria. The 
polymers were active against community-acquired methicillin-resistant S. aureus (CA-MRSA), 
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with similar MIC values against the susceptible S. aureus strain. The general trend of the 
polymers for lower activity towards Gram-negative bacteria may be, at least in part, due to the 
inability of polymers to penetrate the outer membrane of Gram-negative bacteria. This would 
prevent polymer access to the cell wall and cytoplasmic membranes, although the antimicrobial 
target of polymers in bacteria is not clear at this point. The P-polymers were not active against E. 
faecalis while the series of polymers (AEMPs) studied in Chapter 2 were active. It is not clear at 
this point why the results contradict each other. It could be due to the difference in the end 
groups of polymer chains, which have been reported to impact the antimicrobial activity of 
polymers.
24
 
92
 The hydrophobic or hydrophilic nature of end-groups may affect the binding of 
polymers to bacterial cell walls and possibly cell membranes, resulting in different antimicrobial 
activities. To determine this, systematically changing the polymer’s end groups would provide 
new insight into the role of the end groups of polymers on antimicrobial activity. It would be 
possible to incorporate different end groups such as varied lengths of alkyl groups using the 
corresponding RAFT agents.
92
 Changing end groups of polymers likely results in changes to the 
polymers’ hydrophobicity and subsequently changes their interaction with bacterial cell walls. 
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Table 3-3. The antimicrobial spectrum and hemolysis of polymers with primary and quaternary 
ammonium groups. 
Polymer MW 
MIC (μg/mL) (or µM)a 
Gram-positive bacteria  Gram-negative bacteria 
S. aureus 
S. aureus 
(CA-MRSA 
E. 
faecalis 
 
E. coli 
P. 
aeruginosa 
A. 
baumannii 
P115 28,200 47 (1.7) 59 (2.1) 708 (25)  219 (7.8) 188 (6.7) 188 (6.7) 
P92 22,600 39 (1.7) 26 (1.2) 
>1000 
(>44) 
 
156 (6.9) 167 (7.4) 125 (5.5) 
P27 6,700 109 (16) 42 (6.3) 729 (109)  625 (93) 438 (65.4) 750 (112) 
P24 5,900 109 (19) 55 (9.3) 708 (120) 
 625 
(106) 
313 (53.1) 500 (85) 
P17 4,300 55 (13) 52 (12.1) 750 (174) 
 500 
(116) 
438 (102) 750 (174) 
Q37 7,800 20 (2.6) 8 (1.0) 
>1000 
(>128) 
 >1000 
(>128) 
271 (35) nd 
Q32 6,800 22 (3.2) 12 (1.8) 
>1000 
(>147) 
 >1000 
(>147)  
500 (74) nd 
Q19 4,100 23 (5.6) 10 (2.4) 
>1000 
(>244) 
 >1000 
(>244) 
>1000 
(>244) 
nd 
Q11 2,400 16 (6.7) 13 (5.4) 
>1000 
(>417) 
 >1000 
(>417) 
>1000 
(>417) 
nd 
Q10 2,200 29 (13) 10 (4.5) 
>1000 
(>455) 
 >1000 
(>455) 
688 (313) nd 
Q9 2,000 26 (13) 16 (8.0) 
>1000 
(>500) 
 >1000 
(>500) 
>1000 
(>500) 
nd 
a) MIC values are the average of at least two experiments, performed in triplicate. The MIC in µM is 
presented in parenthesis.  
b) Community –associated methicillin resistant S. aureus  
 
The MIC values of the P-polymers do not appear to significantly depend on the polymers’ 
DP, similar to the polymers prepared by RAFT polymerization (Chapter 2). Both the P-polymers 
and Q-polymers showed lower MIC values for S. aureus than other bacteria. Furthermore, the 
activity of the Q-polymers likewise does not appear to be dependent on the DP or the number of 
cationic groups in a polymer. Similar to the P-polymers, Q-polymers are also selective to S. 
aureus over other bacteria. When compared to the P-polymers, the Q-polymers showed larger 
MICs for Gram-negative bacteria, indicating that they are less active towards these bacteria than 
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the P-polymers. While some of the P-polymers are active against E. coli, none of the Q-polymers 
are active against E. coli.  
 
 
Figure 3-8. Activity spectrum of A) Polymers with Primary Ammonium groups (P-polymers) 
and B) Polymers with Quaternary Ammonium groups (Q-polymers). 
 
The effect of the difference in the ammonium structures of the polymers (primary vs. 
quaternary ammonium groups) on their antimicrobial activity were compared more specifically 
by examining the MIC values of polymers P17 and Q19, which have similar degrees of 
polymerization (DP) (Figure 3-9). Because of differences in molecular weights of these 
polymers, the comparison of MIC in µg/mL does not reflect the activity of each polymer chain. 
To end, the MIC values are given in µM (Table 3-3, Figure 3-9). 
 Against S. aureus, the polymers P17 and Q19 showed an MIC of 12.7 ± 3.6 μM and 5.7 ± 
5.9 μM, respectively, indicating that there was no difference in the antimicrobial activity of P- 
and Q-polymers.  The P-polymers and Q-polymers also show similar levels of antimicrobial 
activity against the other bacterial strains tested – E. faecalis, E. coli, and P. aeruginosa. Against 
E. coli, the polymers showed similar activity with the MIC of P17 = 116 ± 0 μM and MIC of Q19 
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= 213 ± 61 μM. These MICs are on the same order of magnitude and are not considered to be 
significantly different.  
 
Figure 3-9. Minimum inhibitory concentrations of polymer with primary ammonium groups P17 
and polymer with quaternary ammonium groups Q19 against selected bacteria. The MIC values 
are presented in µM.   
 
These series of P and Q-polymers are likely to bind to the anionic phosphate groups of 
teichoic acids found in the S. aureus cell wall. Our laboratory has previously demonstrated that 
the primary amine groups of polymers have a higher binding affinity for the phosphate head 
groups of lipids when compared to Q-polymers. This is possibly due to combination of hydrogen 
bonding and electrostatic interaction between primary ammonium groups of polymers with 
phosphate groups of lipids, resulting in the formation of more stable complexes, as the 
quaternary ammonium groups are not capable of forming hydrogen bonds.
77
 We would expect 
this relationship to be reflected in the polymers’ MIC values, with the P-polymers being more 
active than the Q-polymers. Alternatively, quaternary ammonium groups are cationic at any pH, 
while not all primary amine groups are cationic (protonated) at neutral pH. From this trait, we 
would expect there to be stronger attraction between the bacteria and the Q-polymers due to the 
increased charged differential, resulting in a lower MIC (or more potent activity against bacteria) 
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for the Q-polymers over the P-polymers.  However, the similarity in antimicrobial activities of P-
polymers and Q-polymers demonstrated above do not clearly show which cationic polymer 
characteristic is more important for antimicrobial activity. Both polymer groups maybe equally 
attracted to and able to bind with the teichoic acids in S. aureus. However, the polymers did not 
show significant activity against Gram-positive E. faecalis, which also has teichoic acids in the 
cell wall. Teichoic acids may not be the only component involved in the polymers’ antimicrobial 
mechanism. It is possible that the polymers have multiple targets – with teichoic acid being just 
one component of their antimicrobial mechanism. Alternatively, the polymers may target other 
intercellular targets such as lipid II, or processes synthesizing nucleic acid or DNA. 
11
  
Antimicrobial Activity in the Presence of Serum 
 To evaluate the activity of AEMPs in physiological conditions, the MIC values of 
AEMPs were determined in the presence of fetal bovine serum (FBS). It has been reported that 
the activity of antimicrobial peptides is reduced in the presence of serum because the serum salts 
curtain the electrostatic binding of cationic peptides to anionic bacterial surfaces and serum 
proteins such as albumin non-specifically bind to peptides.
41,42 
Therefore, the activity of AEMPs 
could also be mitigated in the presence of serum.  
AEMP activity was determined in 50% (v/v) FBS in MH broth (MHB). MHB 
components could non-specifically bind to the polymers, reducing the polymer activity. The 
reduction of these antagonizing factors in MHB by dilution with PBS buffer would increase their 
antimicrobial activity (decrease MIC values). To take this dilution effect into account, we used 
50% PBS buffer in MH broth as a control. 
 50 
 
 
Table 3-4. The antimicrobial activity of P20 and Q19 in the presence of fetal bovine serum. 
Bacteria Condition 
MIC (μg/mL) 
P17 Q19 CTAB Mupirocin Norfloxacin 
E. coli 
MHB 500 >500 7.8 nd nd 
50% PBS 187.5 62.5 3.9 nd nd 
50% FBS > 500 >500 62.5 nd nd 
S. aureus 
MHB 104.2 7.8 0.975 0.5 1.3 
50% PBS 26.0 2.93 0.975 0.5 1.0 
50% FBS 7.8 13 >7.8 >4.0 2.0 
 
 
Figure 3-10. The effect of FBS on the activity of P17 and Q19 against E. coli and S. aureus. 
  
Against E. coli both P17 and Q19 did not show any activity in the presence of FBS (MIC > 
500 μg/mL), although neither polymer was especially active against E. coli in MHB. The MIC of 
the cationic surfactant CTAB also increased in 50% FBS, indicating serum components 
generally reduced the activity of cationic polymers and surfactants. 
Interestingly, the effects of FBS on the MICs for S. aureus are different for P17 and Q19. 
The MIC of P17 decreased in the presence of FBS (MIC = 7.8 μg/mL) when compare to its 
activity in MHB (MIC = 104.2 μg/mL) or PBS (MIC = 26.0 μg/mL), indicating an increase in 
the antimicrobial activity of P17. We should note that the mechanism of activity enhancement of 
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the polymers with primary ammonium groups in FBS is not clear at this point. The MIC of P17 
showed a 4-fold reduction in PBS/MHB, indicating that the MIC reduction of P17 in FBS is not 
due only to the effect of dilution of MH broth as described above. On the other hand, the MIC of 
Q19 appears to show little variance regardless of whether the polymer is in MHB (MIC = 7.8 
μg/mL), PBS (MIC = 2.93 ± 0.98 μg/mL), or FBS (MIC = 13 ± 2.3 μg/mL). This indicates that 
serum components have little effect on the antimicrobial activity, and possibly the antimicrobial 
mechanism, of Q19. For comparison, the MIC values of both the surfactant CTAB and the 
antibiotic mupirocin significantly increased in 50% FBS, indicating that FBS does not generally 
increase S. aureus susceptibility to antimicrobials. 
Hemolytic Activity 
 As an initial metric of biocompatibility, the lysis of human red blood cells (hemolysis) 
by AEMPs was measured. In general, the Q-polymers showed no hemolytic activity while the P-
polymers showed less than 40% hemolysis up to the highest concentration tested (Figure 3-12). 
The P-polymer (P17) showed 38% hemolysis at 500 μg/mL, the highest concentration tested. It 
should be noted that other P-polymers, with different end groups, showed less than 5% 
hemolysis at 500 μg/mL (Chapter 2). It is known that deprotection of Boc groups by TFA 
produces carbocations in peptide synthesis, which may react with amino acid side chains 
including the aromatic rings of tryptophan and tyrosine, giving t-butyl compounds  
 
Figure 3-11 Boc deprotection by TFA 
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Although the polymers have no aromatic groups, the carbocation may also react with the 
polymer backbone or side chains. This side reaction would modify the polymers with t-butyl 
groups although the modification of polymers cannot be identified in 
1
H NMR spectra. The t-
butyl modification would be likely increase the hydrophobicity of polymers, which increase the 
hemolytic activity of polymers.  
P-polymers were also slightly hemolytic, with polymers P92, P27, and P24 causing 13%, 
2%, and 3% hemolysis at the same concentration. For comparison, Q19 showed 0.6% hemolysis 
at 500 μg/mL while Q37, Q32, and Q10 showing similar values (0.6%, 0.9%, and 0.5%, 
respectively) (Figure 3-12). This indicates that the P-polymers are slightly more potent 
hemolysins than the Q-polymers, although neither is as hemolytic as the bee venom toxin 
melittin (100% hemolysis at 33 μg/mL).  
 
Figure 3-12. Hemolytic activity of AEMPs against human red blood cells, with the hemolysis by 
Triton X as 100%. 
 
Activity against S. aureus Mutants 
 The results described above indicated that the polymer with primary ammonium groups 
P17, as well as the quaternary ammonium polymer, Q19, showed potent antimicrobial activity 
against S. aureus. Our central hypothesis is that electrostatic binding of cationic polymers to the 
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anionic cell wall biopolymers is the dominant factor in the mechanism of cationic methacrylate 
homopolymers. According to this hypothesis, a higher net negative charge density of S. aureus 
cell walls should increase the antimicrobial activity of cationic polymers. Accordingly, the 
antimicrobial activity of the polymers was assessed against S. aureus strain SA113 (parent) and a 
dltA strain (mutant) in the same SA113 background. DltA is a D-alanine-D-alanyl carrier protein 
that is responsible for the biosynthesis and degradation of murein sacculus and peptidoglycan.
93
 
The products of dlt genes catalyze D-alanylation which is necessary for the modification of both 
lipoteichoic acids and wall teichoic acids. 
94,56,95
 Alanylation adds positive charge onto the 
teichoic acids (Figure 3-3). The dltA mutant lacks this protein, and is no longer able to add 
positive charge to the teichoic acids, making the mutant cell more negatively charged than the 
wild type.  It has been reported that S. aureus has become resistant to cationic antimicrobial 
peptides by this alanylation.
46
 The alanyl esterification of the teichoic acids reduces the net 
anionic charge in the S. aureus cell wall,
47,48
 which decreases the electrostatic binding of cationic 
polymers to the bacterial cell surfaces. Therefore, we expected that the cationic polymers would 
show higher activity against the mutant than the parent due to the higher net negative charge in 
the cell wall of mutant if electrostatic binding is a key determinant in the antimicrobial 
mechanism.  
 54 
 
 
 
Figure 3-13. MIC of P17 and Q19 against S. aureus and bacterial mutants. 
  
The activity of Q19 increased about 2.5 times from an MIC of 41.7 μg/mL against the 
SA113 parent to an MIC of 15.6 μg/mL against the dltA mutant. The activity of P17 increased 
approximately 16 times from an MIC > 500 μg/mL against the parent to an MIC of 31.3 μg/mL 
against the mutant. These results indicate that both polymers were more active against the dltA 
mutant than the SA113 parent strain (Figure 3-13). This suggests that an increase of net negative 
charge increases the activity of the polymers. This result supports the proposed mechanism that 
the electrostatic binding of cationic polymers to anionic cell walls is a key factor in the 
mechanism. Interestingly, although P17 did not show any significant activity against the parent 
SA113, P17 and Q19 are both active against the dltA mutant with similar MIC values.  
 
Conclusion 
In summary, we investigated the in vitro activity of series of polymers with primary (P-
polymers) or quaternary ammonium groups (Q-polymers) in the side chains to determine the 
effect of cationic group on a polymer’s antimicrobial activity. Both P-polymers and Q-polymers 
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were more active towards S. aureus, than the other bacteria tested (E. faecalis, E. coli, and P. 
aeruginosa).  There was little difference in the activity between P-polymers and Q-polymers for 
the tested bacterial strains. Both polymers showed similarly potent activity in the presence of 
serum. P-polymers were somewhat hemolytic at higher concentrations (38% hemolysis at 500 
μg/mL), while most P-polymers showed less than 10% hemolysis at the same concentration. Q-
polymers were nonhemolytic, showing less than 0.6% hemolysis at the same concentration. The 
polymers were more active against the cell wall mutant which has a more negatively charged cell 
wall than the wide type. This result supports our hypothesis that electrostatic binding of cationic 
polymers to the anionic cell wall biopolymers is an important factor in the mechanism of cationic 
methacrylate polymers, although whether electrostatic binding is the only factor in the 
antimicrobial mechanism of these polymers remains to be proven. While we hypothesized that 
polymers with quaternary ammonium groups would be more effective against S. aureus than 
polymers with primary ammonium groups, this hypothesis is not supported by these results. Q-
polymers showed similar, but not better, activity than P-polymers against S. aureus both in MHB 
and in FBS. While these assays failed to distinguish the differences, if any, in antimicrobial 
mechanism of the P-polymers and Q-polymers, additional research may reveal differences. It 
would be beneficial to determine if the polymers localize at different areas of bacterial cells 
through fluorescence imaging of dye-labeled polymers with bacteria. This would provide 
information on the bacterial structures where the polymers act. Furthermore, data on the 
bactericidal kinetics of each polymer would reveal if the polymers are effective on different time 
scales. This could then be correlated to the polymers targeting different cell processes including 
DNA replication, cell wall growth, and cell splitting, as each event occurs at a specific time in 
the bacteria’s growth cycle. These results could help determine if the amine structure of the 
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cationic side chain has an impact on antimicrobial activity, or if just having a cationic charge is 
the most important characteristic.  
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Chapter 4 : Antimicrobial Action of Amphiphilic Copolymers Targeting Bacterial Cell 
Membranes 
Background and Previous Results: Osmolysis of Red Blood Cells 
To gain insight into a new design strategy for nontoxic antimicrobial polymers, our 
laboratory previously studied the mechanism of toxicity of amphiphilic copolymers (Fig. 4-1) to 
human red blood cells.  
 
Figure 4-1. Structure of Amphiphilic Methacrylate Random Copolymers. A series of 
polymethacrylate copolymers with primary ammonium side chains and methyl or butyl 
hydrophobic side chains were synthesized by free-radical polymerization by Dr. Ed Palermo. 
 
Colloid-osmotic lysis results when pores are formed in a membrane and there are differences 
in ions or other suspended particles (colloids) between the inside and outside of the membrane. 
Colloid-osmotic lysis of red blood cells (RBCs) is a common cause of hemolysis by many 
peptides,
96, 97, 98
 bacterial toxins,
99,
 
100,
 
101
 and synthetic polymers
102, 103
. Initially, these peptides 
and polymers produce pores in cell membranes which create an osmotic imbalance between the 
inside (cytosol) and outside of the cell. While these pores are too small to allow the efflux of 
macromolecules from the cytosol, including hemoglobin in red blood cells, they do allow for the 
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passage of small solutes such as water and ions. While these small solutes are allowed to 
establish equilibrium between the cytosol and surrounding environment, larger molecules are 
unable to equilibrate, as they are too large to fit through the formed pores. This results in the 
osmolarity of the cytosol exceeding that of the external buffer solution, which contains only 
small molecules. This colloid-osmotic imbalance (hypotonic condition) causes an influx of water 
through the small pores as the system attempts to dilute the macromolecules in the cytosol, 
resulting in cell swelling and compromise of membrane integrity.  The loss of hemolytic activity 
of peptides or polymers upon the addition of large osmolytes such as high molecular weight PEG 
or “osmo-protectants” to the external media is evidence of a colloid-osmolytic mode of action, as 
these large compounds balance the colloid-osmotic pressure across the membrane.  
My contribution to this project was to use an osmoprotection assay to determine if the lytic 
peptide melittin induced hemolysis by colloid-osmotic lysis as a result of pore formation. My 
secondary objective was to estimate pore size caused by melittin if pores were indeed formed. 
The hemolysis of melittin is concentration dependent, with higher concentrations of melittin 
resulting in more hemolysis. PEGs with molecular weights > 1000 protected RBCs against 
hemolysis by melittin (Figure 4-2 and Figure 4-3). PEGs with >1000 MW were able to protect 
the RBCs as their hydrodynamic sizes were larger than the pores in the membrane, reducing the 
osmolarity difference between the cytosol and the buffer solution. The result suggests that 
melittin caused colloid-osmotic hemolysis by forming pores with a diameter of ~ 2.0 nm in the 
cell membranes of RBCs which is in agreement with previous reports.
97
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Figure 4-2. Osmoprotection against hemolysis induced by melittin.
104
 Hemolysis was performed 
at least three times in triplicate in TBS, and determined relative to the positive lysis control 
Triton X-100 (0.2% v/v in water). PEGs were prepared in PBS buffer and added to give a final 
concentration of 30 mM in the assay.  
 
The same assay method was used to determine the osmotic hemolysis by the cationic 
amphiphilic copolymers presented in Figure 4-1. All the assays were conducted by Dr. Iva 
Sovadinova, who is the first author of the published article.
104
 Protection against hemolysis 
induced by PB27 started to be effective in the range of PEG MWs between 600-1000 (Figure 
4-3B). At a polymer concentration of 31 μg/mL, the percent hemolysis decreased as PEG MW 
(and subsequently the hydrodynamic radius of the osmoprotectant) increased (Figure 4-3C). The 
same trend of decreasing hemolysis with increasing PEG MW was observed for melittin at a 
concentration of 4.5 μg/mL. PEG 600 and 1000 have hydrodynamic radii of 0.8 and 1.0 nm 
respectively in water,
105
 indicating that PB27 produced pores 1.6 – 2.0 nm in diameter at a 
polymer concentration of 31 μg/mL. Similarly, PEG 1500 (2.4 nm in diameter) provided 
osmoprotection against hemolysis induced by PM63 while sucrose (0.92 nm diameter) did not 
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affect the hemolysis (Figure 4-3B). These results indicate that the polymers produce nanosized 
pores in the RBC membranes, leading to an influx of small solutes and osmotic lysis of RBCs. 
 
 
Figure 4-3. Osmoprotection against hemolysis induced by the copolymers and melittin. (A) 
PB27, (B) PM63, (C) PEG MW dependence of osmoprotection against hemolysis induced by PB27 
at 31 μg/mL or melittin at 4.5 μg/mL. The assays were performed and previously reported by Dr. 
Iva Sovadinova.
104
 
 
Current Efforts 
Several models for the mechanism of antimicrobial peptides have been proposed, including 
pore formation, non-specific disruption, and lipid phase separation (Figure 1-3). Previous 
research in our laboratory, outlined above, demonstrated that cationic amphiphilic methacrylate 
random copolymers induce hemolysis by the formation of nano-sized pores (~1-2nm) in cell 
membranes, resulting in osmolysis.
104
 It has been also previously reported that Another AMP 
mimic, a synthetic antimicrobial peptide (CM15) which is a hybrid AMP of cecropin A and 
melittin, exert its antimicrobial effect through the formation of nano-sized pores (2.2-3.8 nm) in 
bacterial cell membranes, followed by osmolysis.
106
 Based on these results, we hypothesized that 
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the mechanism of antimicrobial action exerted by the amphiphilic copolymers involves 
membrane pore formation, followed by osmolysis.  
To test our hypothesis, we used an osmoprotection assay described below, which determines 
the effect of osmolytes on the antimicrobial activity of polymers. We used a variety of cationic 
methacrylate polymers with primary ammonium side chains. A random copolymer, a cationic 
homopolymer, and a block copolymer were used to determine the effect of polymer architecture 
on the antimicrobial mechanism of polymers.  
 
Polymer Synthesis and Characterization 
A series of cationic amphiphilic copolymers containing primary amine groups as cationic 
functionality and ethyl groups as hydrophobic side chains were prepared by Dr. Enrico Nadres 
using RAFT polymerization. To determine if the amphiphilic structures of the polymers had any 
impact on its antimicrobial mechanism, the series of polymers included a random copolymer 
(EN-A), a homopolymer (EN-B), and a block copolymer (EN-C). Branched (BPEI) and linear 
(LPEI) poly(ethylene imine)s were also tested for comparison. These PEIs have been reported to 
show antimicrobial activity against E. coli and S. aureus.
30
 Dr. Haruko Takahashi evaluated the 
antimicrobial and hemolytic activities of the RAFT polymers. The random copolymer EN-A 
showed potent activity, but also high hemolytic activity (HC50 = 6 µg/mL), indicating this 
polymer is not cell-selective. On the other hand, homopolymer EN-B did not show any activity 
against E. coli, but did show activity to S. aureus, in agreement with our previous results 
(Chapters 2 and 3). The block copolymer EN-C also showed similar selective activity to S. 
aureus over E. coli. Neither EN-B nor EN-C showed any significant hemolytic activity up to the 
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highest concentration tested (1000 µg/mL), indicating that these polymers are selective to S. 
aureus over E. coli and RBCs. The BPEI and LPEI are active against both E. coli and S. aureus.  
 
Figure 4-4. Structure of Amphiphilic Methacrylate Polymers. The polymers were previously 
syntheised by Dr. Enrico Nadres.  
Table 4-1. Characterization and Activity of Amphiphilic Methacrylate Polymers and Controls.
a
 
     MIC (μg/mL) 
HC50
 
(μg/mL) 
Polymer %A %B DP
b
 Mn
c
 E. coli S. aureus 
EN-A 50 50 23.5 3,300 7.8 15.6 6 
EN-B 100 0 26.2 3,600 >1000 62.5 >1000 (4.8%) 
EN-C 46 54 80 9,900 >1000 62.5 > 1000 (30.9%) 
BPEI - - - 1,800 250
d 
32
d 
>4000 (2%)
d 
LPEI - - - 2,500 31
d 
8
d 
565 ± 104d 
a) The polymers were synthesized and characterized by Dr. Enrico Nadres. The MIC and 
HC50 were previously determined by Dr. Haruko Takahashi. 
b) The degree of polymerization was determined by comparing the integrated intensities of 
the 
1
H NMR resonances from the terminal RAFT agent group relative to the monomer 
side chain. 
c) The number-average molecular weights (Mn) were calculated using DP and the molecular 
weights of monomer and RAFT agent based on the chemical structure of polymers. 
d) Values taken from paper Gibney, K.A. et al.30 
 
The Effect of Osmolytes on Antimicrobial Activity of Polymers 
To determine if the polymers exert their antimicrobial activity by osmotic lysis of bacterial 
cells, the effect of osmolytes on the growth inhibition of bacteria by the polymers was 
determined. If the inhibitory effects of the polymers were antagonized by osmolytes or the 
bacteria were protected, an increase in MIC would be detected. As demonstrated for the 
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mechanism of polymer-induced hemolysis, if the polymers form nano-sized pores the increase in 
MIC would also depend on the size of osmolytes. In these experiments, the polymers were 
incubated with either E. coli or S. aureus in MH broth containing a 10 mM concentration of an 
osmolyte listed in Table 4-2. After incubation for 18 hours at 36°C, MIC was determined as the 
polymer concentration necessary to completely inhibit bacterial growth.  
 
Table 4-2. Osmolytes and their hydrodynamic radii 
Osmolytes hydrodynamic radii (nm)
107
 
glucose 0.72 
sucrose 0.98 
PEG 400 1.12 
PEG 600 1.38 
PEG 1000 1.78 
PEG 1500 2.2 
PEG 2000 2.54 
PEG 4000 3.2 
 
 For both E. coli and S. aureus the presence of osmoprotectants in the growth media had 
little effect on the MIC value for any of the polymers tested (Figure 4-5). For E. coli the MIC of 
the random copolymer EN-A is 9.1 μg/mL in the presence of sucrose (rh = 0.72 nm), and the 
MIC value remains the same even in the presence of the osmoprotectant with the largest 
hydrodynamic radius, PEG4000 (rh = 3.2nm). MIC values were likewise maintained upon 
exposure to each osmoprotectant for the remaining polymers. Likewise, MICs against S. aureus 
in the presence of osmoprotectants seem to vary very little, regardless of hydrodynamic radius.  
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Figure 4-5. Osmoprotection against hemolysis induced by the polymers and PEIs. 
 
 If the chief antimicrobial mechanism of any of the polymers tested here were colloid-
osmotic lysis, we would expect the polymers to show less activity in solutions of 
osmoprotectants with hydrodynamic radii larger than the pores formed by the polymer. As this 
assay result does not demonstrate any change in MIC in the presence of a variety of 
osmoprotectant solutions, these results seem to reject our hypothesis of antimicrobial activity as 
a result of colloid-osmotic lysis. It is possible that these polymers may disrupt bacterial 
membranes in a non-specific manner rather than through the formation of discrete membrane 
pores.  
Another possibility is that these assay results were obscured by the contents of MHB.  
While performing the assay in MHB does enable us to observe the effect of osmoprotectants on 
the MIC of bacteria under a growing condition, MHB is comprised of many components 
including acid hydrolysate of casein, beef extract, and starch.
108
 It may be advantageous to repeat 
this experiment in a buffer solution, such a phosphate buffered saline (PBS), where the exact 
environmental composition is known in case any components of MHB or PBS have an effect on 
the antimicrobial activity of the polymers in the presence of osmoprotectants.    
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Conclusion 
 Although previous studies have shown methacrylate copolymers causing colloid-osmotic 
lysis of RBCs, it does not necessarily follow that the polymers also cause colloid-osmotic lysis as 
their primary mechanism of antimicrobial activity. Varying the hydrodynamic radius of 
osmoprotectants in the system did not cause a significant change in the minimum inhibitory 
concentration of the polymers when tested against either E. coli or S. aureus. This assay rejects 
our hypothesis that the copolymers cause colloid osmotic lysis of bacterial cells. Going forward, 
it is important to clarify if the polymers exert their bactericidal activity through membrane 
disruption as a result of pore formation, or if another mode of action is more prominent. Since 
the polymers have different structures, a random copolymer, a cationic homopolymer, and a 
block copolymer, as well as different antimicrobial activities, we expected that they would show 
differences in their antimicrobial mechanism. It is possible that MHB obfuscated the results, as 
MHB consists of various ions and proteins that may interfere with the osmoprotection. To avoid 
this, the osmoprotection assay should be repeated in PBS buffer or another more controlled 
buffer. Further studies to reveal the antimicrobial mechanism, as presented in the conclusion, 
would enable us to better correlate the structure/ activity relationships of antimicrobial polymers.  
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Chapter 5 : Conclusions and Future Directions 
At the outset of my research, the central hypothesis was that cationic polymers would be a 
new synthetic platform for potent and selective anti-S. aureus agents. These new anti-S. aureus 
agents would have limited toxicity and a antimicrobial mechanism that did not rely on membrane 
disruption. Toward that end, the antimicrobial activity and mechanism of cationic methacrylate 
homopolymers were investigated.  
Chapter 2 examined the bacterial-strain specificity of cationic methacrylate homopolymers, 
as well as their suitability for in vivo treatment of S. aureus infections. The methacrylate 
homopolymers with primary ammonium groups in the side chains (ammonium ethyl 
methacrylate homopolymers, AEMPs) were more active against S. aureus than E. coli without 
causing hemolysis of red blood cells. They also showed potent activity against S. aureus in the 
presence of serum, suggesting that the polymers may be active against S. aureus infections in 
physiological conditions. The exposure of AEMPs to S. aureus bacteria resulted in the 
development of resistance in S. aureus (6 times increase in MIC), which was comparable that 
caused by the conventional antibiotic mupirocin. Under the same conditions, the exposure of S. 
aureus to norfloxacin resulted resistance development (64 times increase in MIC). The cationic 
homopolymer AEMPs without strong hydrophobic moieties can exert antimicrobial activity, 
especially in the presence of serum. In a cotton rat nasal infection model, the AEMPs 
significantly reduced the number of viable S. aureus cells when compared to the non-treatment 
control.  
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Chapter 3 discussed the antimicrobial mechanism of cationic methacrylate homopolymers, 
focusing on efforts to improve upon the electrostatic interaction between the cationic 
homopolymers and the anionic bacterial cell walls. To that end, the antimicrobial activity of 
methacrylate polymers with primary ammonium side chains (P-polymers) and polymers with 
quaternary ammonium side chains (Q-polymers) were examined. The hypothesis was that the 
polymers with quaternary ammonium groups would be more efficient in growth inhibition of S. 
aureus than their counterparts with primary ammonium groups because quaternary ammonium 
groups are not pH-dependent. While both polymer groups were more active towards S. aureus 
strains than other bacteria tested, there was little difference in activity between the P-polymers 
and the Q-polymers. As both groups of polymers were active against S. aureus in serum, the 
polymers could be used in vivo without losing antimicrobial activity. These polymers are both 
more active against a S. aureus mutant deficient in cell wall alanylation which has higher net 
negative charge in the cell wall than the wild type.  This result supports our hypothesis that 
electrostatic binding of cationic polymers to the anionic cell wall biopolymer is an important 
factor in the mechanism of cationic methacrylate polymers. However, it remains unclear if 
electrostatic binding is the dominant factor in the mechanism. Our hypothesis that polymers with 
quaternary ammonium groups would be more effective anti-S. aureus agents was not validated, 
as the Q-polymers showed similar, but not better, activity when compared to P-polymers.  
Chapter 4 examined the antimicrobial mechanisms of amphiphilic methacrylate polymers in 
relation to pore formation in bacterial cell walls and subsequent osmotic lysis. While amphiphilic 
methacrylate polymers have been shown to cause colloid-osmotic lysis of red blood cells, our 
experiments rejected the hypothesis that polymers cause pore formation and subsequent colloid-
osmotic lysis in bacterial cells. While bactericidal activity through colloid-osmotic lysis was one 
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hypothesis for the antimicrobial activity of these polymers, many other possible modes of action 
exist. It would be beneficial to test other membrane permeabilization methods as well as methods 
targeting intracellular components and processes.  
These results indicate that AEMPs can serve as a new design strategy for antimicrobial 
polymers effective in physiological conditions. While many other AMPs may lose their activity 
in serum, the antimicrobial activity of our polymer improves in serum, enabling lower dosing for 
effective treatment than other compounds. Considering their activity in vitro and preliminary in 
vivo investigations, it is reasonable to propose that these polymers have potential for applications 
in topical anti-infective creams, wound dressings, and implants or biomedical devices.  
While these AEMPs have potential for use as polymeric antimicrobials, there are still 
problems and questions that need to be addressed. While the AEMP with the least number of 
cationic groups was the most nontoxic against HEp-2 and COS-7 cells, it would be ideal design a 
polymer with even lower toxicity. One approach to lower toxicity would be to incorporate non-
toxic segments into the polymer structure. For example, the methacrylate could be 
copolymerized with polyethylene glycol (PEG) or another nontoxic polymer, ideally imparting 
more cytocompatibility to the cationic methacrylates.  PEGs itself shows little or no 
antimicrobial activity, and direct incorporation into the polymer may have little effect on the 
polymer’s antimicrobial activity if the number of cationic charges remain the same. However 
depending on the method of incorporation of PEG, spacing between cationic charges may 
change, which could have an effect on the antimicrobial activity. An optimal PEG/ cationic 
polymer structure would have to be determined. Another approach would be to decrease the 
number of cationic charges on the polymer chain. P7.7, with 7.7 amine groups and possibly 7.7 
positive charges depending on the pH of the environment, was the least nontoxic of the AEMPs 
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synthesized. It would be interesting to determine if P6 or P5 or smaller polymers, perhaps even 
oligomers, still retain their selectivity to S. aureus while decreasing or eliminating toxicity to 
HEp-2 cells. Previous studies have indicated that cytotoxicity is likely related to the spacing of 
the cationic charge of the polymer when it interacts with the mammalian cell. Spacing between 
cationic charges should be manipulated, both increasing and decreasing spacing, to determine the 
optimal spacing distance for antimicrobial activity and biocompatibility.  
While in vitro experiments are an important tool to examine cytotoxicity, ultimately the 
commercialization of the drug relies on in vivo experiments. Although preliminary in vivo 
experiments were performed and no animals perished during treatment, more information about 
the pharmacokinetics or the movement of drugs within the body, of the antimicrobial is 
necessary before commercialization. Furthermore, we need to understand the bio distribution of 
the polymer to ensure dangerous complications do not arise from the use of this antibiotic.   
Upon completion of this research project, it still remains unclear how the AEMPs exert their 
antimicrobial mechanism.  We continue to hypothesize that our AEMPs act using an 
antimicrobial mechanism that does not cause membrane disruption. Cationic BPEIs have not 
demonstrated membrane depolarization, as previously discussed.
30
 Furthermore, chitosan, a 
cationic natural polysaccharide active against S. aureus without causing membrane damage, 
likely impacts membrane-bound energy generation pathways that ultimate lead to cell death.
34
 
The first steps in our investigation would be to confirm that AEMPs do not cause membrane 
disruption. Monitoring the potassium ion flux in suspensions of bacterial cells using a K
+
-
specific ion electrode would allow us to detect membrane impairment and leakage of cellular 
components upon exposure to different concentrations of AEMPs. Typical pore-formers 
(membrane disruptors) such as nisin typically show complete leakage of K
+
 ions from bacterial 
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cells, while gradual or non-leaking compounds are not likely to have pore-formation as their 
primary mechanism of antimicrobial activity.
11
 Further evidence about membrane disruption 
could be gathered by using liposomes as a simple model to observe the interaction between the 
AEMPs and model bacterial lipid membranes. We could encapsulate fluorescent compounds of 
various sizes in the liposomes and monitor leakage of fluorescent components upon exposure to 
various AEMP concentrations. If the AEMPs formed pores, we would expect an efflux of 
molecules smaller than the pores from the liposomes as the system works to reestablish 
equilibrium. We could compare results from AEMP/liposome interactions with liposomes 
exposed to pore-formers, such as nisin or melittin, to identify if AEMPs cause membrane 
disruption through pore formation. 
If we confirm that AEMPs do not cause membrane disruption as we hypothesize, additional 
actions could help determine the polymers’ antimicrobial mechanism. Due to the cationic charge 
of the AEMPs, interactions between the polymers and teichoic acids may be important. 
Preliminary investigations in Chapter 3 determined that the cationic homopolymers were more 
attracted to a S. aureus mutant deficient in alanination in the cell wall teichoic acid, a compound 
that normally makes S. aureus cell walls less negatively charged. It would be interesting to 
expand upon this research, testing the antimicrobial activity of the polymers against other 
mutants lacking one or more genes involved in the biosynthesis of teichoic acid. If the polymers 
do target teichoic acid, a negatively charged biopolymer, due to electrostatic interactions, we 
would want to confirm that the polymers are less active against a more positively charged S. 
aureus mutant – perhaps a mutant with a higher percentage of alanine. Monitoring the activity of 
the AEMPs against S. aureus without teichoic acids would reveal if teichoic acids are essential 
for the AEMPs’ antimicrobial mechanism,109 or if teichoic acid is just one of many components 
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the polymers target in bacterial cells. To get an even more detailed picture of the polymer’s 
antimicrobial mechanism, analysis of the transcriptional response pattern through the use of 
genome-scale microarrays would identify the fine-tuned responses of bacteria to stress.
11
 
Identifying which genes are up or down regulated would give us an indication of the intracellular 
targets of these AEMPs. This information could be compared to the gene expression information 
of other antimicrobials, such as chitosan, to determine the relationship between antimicrobial 
mechanism and structure of the antimicrobial. 
We hypothesize that amphiphilic copolymers are likely to act by membrane disruption. The 
amphiphilic copolymers are more structurally similar to membrane disrupting AMPs, having 
both hydrophobic and hydrophilic segments. Additionally, the amphiphilic random copolymers 
show a broad spectrum of activity, whereas the cationic homopolymers show more selective 
antimicrobial activity. It is likely that the increased hydrophobicity of the amphiphilic copolymer 
is responsible for this difference in antimicrobial activity, as the hydrophobicity enhances 
insertion of the polymers into the hydrophobic region of cell membranes. Osmoprotection assays 
in Chapter 4 rejected the hypothesis that the polymers caused colloid-osmotic lysis of bacterial 
cells. While it would be beneficial to repeat the assay in a more defined buffer such as PBS, 
experiments monitoring potassium leakage from cells as well as pore formation on liposomes 
could help identify the antimicrobial mechanism of random amphiphilic copolymers. Identifying 
the mechanism of both cationic homopolymers and random amphiphilic copolymers would 
better help us understand the relationship between a polymer’s structure and its antimicrobial 
activity, providing scaffolds for future polymeric antimicrobial design. 
Overall, this research demonstrated that AEMPs have potential for use as scaffolds in the 
design of strain-specific antimicrobials that are active in vivo. These AEMPs lack a distinct 
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hydrophobic segment found in many AMPs and synthetic polymers, but despite this omission 
they still are effective against bacteria. This work will provide inspiration for the development of 
other polymer antimicrobials with antimicrobial activity specific to target bacterial strains, and 
may eventually help stem the tide of the development of drug-resistant bacteria.  
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APPENDIX A  
Materials and Methods 
Materials 
2,2’-Azobisisobutyronitrile (AIBN) was purchased from Sigma-Aldrich, and ethanolamine and 
di-tert-butyldicarbonate were purchased from Acros and used without further purification. 
Methacryloyl chloride was purchased from Acros and was freshly distilled prior to each use. 
Trifluoroacetic acid and reagent grade solvents were purchased from Fisher, and the bee venom 
toxin melittin (>85%) was purchased from Sigma. Poly(ethylene glycol) (PEG, MW = 2,000, 
cat. 81221, lot 1237799 14006162) was purchased from Sigma-Aldrich and  branched PEI 
(BPEI, MW = 1800, cat. 06089, lot 559792) was purchased from Polysciences, Inc. (Warrington, 
PA, USA). The remaining PEGs were purchased from Acros Organics.  Human RBCs 
(leukocytes reduced adenine saline added) were obtained from the American Red Cross Blood 
Services Southeastern Michigan Region and used prior to the out date indicated on each unit. 
Heat-inactivated fetal bovine serum (HI FBS), certified and of US origin (cat 10082-147, lot 
1382252) was purchased from Life Technologies (Gibco). RAFT agent 2-cyanoprop-2-yl ethyl 
trithiocarbonate (CPETC) was synthesized as previously described.
25 
For cytotoxicity testing, 
HEp-2 (ATCC
®
 CCL-23) and COS-7 (ATCC
®
 CRL-1651) cell lines were used. Gel permeation 
chromatography (GPC) was performed using a Waters 1515 HPLC instrument equipped with 
Waters Styragel®
 
(7.8 x 300 mm) THF HR 0.5, THF HR 1, and THF HR 4 type columns in 
sequence and analyzed with a differential refractometer (RI) at 40°C in THF. Samples were 
dissolved in THF and passed through a 0.2 μm PTFE filter prior to analysis.  The number-
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averaged molecular weight (Mn) and weight-average molecular weight (Mw) were calculated 
using a calibration curve based on 10 standard samples of poly(methyl methacrylate), MW 500 – 
50,000 (Agilent Technologies,  M-L-10, No. PL2020-0100). 
1
H NMR was performed using a 
Varian MR400 (400 MHz) and analyzed using VNMRJ 3.2 and MestReNova.  
Monomer Synthesis 
 
Figure A-1. Synthesis of monomer 2-(tert-butoxycarbonylamino) ethyl methacrylate 
 
The monomer was prepared in the same procedure reported previously.
27
 To a solution of 
ethanolamine (116 mmol, 7 mL) in a biphasic mixture of THF (150 mL) and NaOH (aq) (5M, 30 
mL) in an ice bath di-tert-butyldicarbonate (118 mmol, 25.67 g) was added, and the mixture was 
stirred at room temperature overnight.  The solution was concentrated under reduced pressure 
and the resulting N-Boc ethanol amine was washed with ethyl acetate, 10% citric acid, saturated 
NaHCO3 (aq), and brine. The organic layer was dried over magnesium sulfate and filtered. Ethyl 
acetate was removed under reduced pressure. 
1
H NMR (400 MHz, CDCl3): δ1.367 (s, 9 H), 
3.182 (t, 2H), 3.587 (t, 2H), 5.287 (bs, 1H).  
Freshly distilled methacryloyl chloride (51.2 mmol, 5.0 mL) in dichloromethane (20 mL) was 
added dropwise to a solution of the N-Boc-ethanolamine (44.8 mmol, 7.22 g) and triethylamine 
(89.7 mmol, 12.5 mL) in dichloromethane (50 mL) at 0°C, and the mixture was allowed to stir 
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overnight at room temperature. The solution was then filtered, and the filtrate was concentrated 
under reduced pressure and washed with water, 10% citric acid, 10% K2CO3,  saturated NaHCO3 
(aq), and brine. The organic layer was dried over magnesium sulfate, and filtered. The monomer 
2-(tert-butoxycarbonylamino) ethyl methacrylate, was recrystallized from hexanes at -20°C to 
give a white solid in 70.3% yield. 
1
H NMR (400 MHz, CDCl3): δ 1.44 (s, 9 H), 1.94 (s, 3 H), 
3.43 (d, 2 H), 4.20 (t, 2 H), 4.77 (bs, 1H), 5.58 (s, 1 H), 6.12 (s, 1 H).  
Polymer Synthesis 
Synthesis of Methacrylate Polymers with Primary Amine Groups by RAFT polymerization  
Reversible addition-fragmentation chain transfer (RAFT) polymerization of N-(tert-
butoxycarbonyl)aminoethyl methacrylate (Boc-AEMA) was carried out using the RAFT agent 2-
cyanoprop-2-yl ethyl trithiocarbonate (CPETC). Boc-AEMA (1.1947 g, 5.211 mmol) and AIBN 
(8.6 mg, 0.05211 mmol) were placed in a 20 mL flask. After evacuating and refilling the flask 
with nitrogen three times, dry toluene (total toluene volume 7.526 mL, including CPETC 
solution) and dry acetonitrile (5.211 mmol, 0.272 mL) were added to maintain a monomer 
concentration of 0.67M. The mixture was stirred at room temperature until contents were 
dissolved. Finally CPETC (0.5M in toluene) was added at 22, 10, or 3 mol % relative monomer 
(2.3, 1.05, 0.3 mL, respectfully). The reaction flask was then placed in oil bath at 80°C for 48 hrs 
with stirring.  After 48 hrs, the polymerization was quenched by cooling the reaction mixtures in 
a dry ice/ ethanol bath. The percent conversion of monomer was determined by 
1
H NMR by 
monitoring the disappearance of the hydrogens at δ 6.1 and 5.6 in CDCl3. The polymerization 
was concentrated under reduced pressure and the polymer was then precipitated twice in hexane. 
The precipitates were collected by centrifugation and dried under high vacuum overnight to give 
Boc-protected AEMPs (1g, Yield 83%). Boc-protected polymers were characterized by 
1
H NMR 
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and GPC. 
1
H NMR (400 MHz, DMSO-d6) for P7.7: δ 0.85 (d), 1.16 (s), 1.19 (s), 1.31 (bs), 1.62 
(bs), 1.80 (m), 3.17 (bs), 3.85 (bs), 6.81 (bs). See APPENDIX B, or Figure 2-3, for peak 
assignment.  
The Boc-protected polymers (1 g) were dissolved in methanol (0.5 mL). TFA (3 ml) was added 
to the polymer solution, and the reaction mixture was stirred at room temperature for 10 min. 
TFA and methanol was reduced by N2 flushing, and the polymers were twice precipitated from 
methanol into diethyl ether. The precipitates were collected by centrifugation and dried under 
high vacuum. The resultant polymers were further dissolved in water ( ~ 10 mL) and frozen in a 
freezer (0°C) for at least 3 hours and a -80°C freezer overnight. These polymers were then 
lyophilized under high vacuum using Labconco’s FreeZone® 1 Liter Benchtop Freeze Dry 
System (Model 7740021) overnight, affording a powder of homopolymers bearing primary 
ammonium groups in the form of trifluoroacetate salts (0.750, Yield 59%).  The polymers were 
characterized by 
1
H NMR. 
1
H NMR (400 MHz, DMSO-d6) for P7.7: δ δ 0.85 (d), 1.16 (s), 1.25 
(s), 1.63 (bs), 1.91 (m), 3.12 (bs), 4.07 (bs), 8.27 (bs). See APPENDIX B for NMR spectra and 
peak assignment. 
Synthesis of Methacrylate Polymers with Primary ammonium Groups  by Free-radical 
polymerization 
Free-radical polymerization of Boc-AEMA was carried out in acetonitrile using AIBN as the 
initiator and MMP as a chain transfer agent to control the average degree of polymerization (DP). 
Boc-AEMA (200 mg, 0.872 mmol) was dissolved in acetonitrile (0.6 mL) in a borosilicate glass 
test tube. MMP (x ml, x mmol, as a 1.0M solution in acetonitrile) and AIBN (87 μL of 0.1M 
solution in acetonitrile, 0.0087 mmol) were added. The test tubes were sealed with a rubber septa, 
and the solutions were deoxygenated with N2 bubbling for 5 minutes. The tubes were then placed 
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in a 60 -70°C oil bath. After 18 hours, the mixtures, viscous yellow-brown oils, were removed 
from the oil bath. Dichloromethane (0.3 mL) was added to each tube to dissolve the polymer 
then the polymers were then precipitated twice in hexane. The precipitates were collected by 
centrifugation and dried under high vacuum overnight. Boc-protected polymers were 
characterized by 
1
H NMR. 
The Boc-protected polymers (1 g) were dissolved in methanol (0.5 mL). TFA (3 ml) was 
added to the polymer solution, and the reaction mixture was stirred at room temperature for 10 
min. TFA and methanol was reduced by N2 flushing, and the polymers were twice precipitated 
from methanol into diethyl ether. The precipitates were collected by centrifugation and dried 
under high vacuum. The resultant polymers were dissolved in water and lyophilized to afford 
homopolymers bearing primary ammonium groups in the form of TFA salts.  The polymers were 
characterized by 
1
H NMR. 
 
Synthesis of Methacrylate Polymers with Quaternary Ammonium Groups by Free-radical 
polymerization 
Living radical polymerization using methyl 3-mercaptopriopionate (MMP) as the chain transfer 
agent. 2-Methacryloxyethyltrimethylammonium chloride (100 mg, 0.481 mmol, 70% solution in 
water), AIBN (48 μL of a 0.1M solution in methanol, 0.00481 mmol), and MMP (9.02M in 
methanol) was added at 2, 5, 10, or 15 mol% relative monomer (2, 3, 5, 8 μL respectively). The 
reaction vessel was purged with N2 and then placed in an oil bath at 60°C for 18 hours. After 18 
hours, a white gel had formed. The polymers were twice precipitated from methanol into diethyl 
ether. The precipitates were collected by centrifugation and dried under high vacuum. The 
resultant polymers were dissolved in water and lyophilized to afford homopolymers bearing 
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quaternary ammonium groups in the form of chloride salts. The polymers were characterized by 
1
H NMR.  
Antimicrobial Assay 
The minimum inhibitory concentration (MIC) of polymers was determined by a turbidity-based 
microdilution assay according to the procedure reported previously.
27
 Assays were performed in 
Muller Hinton (MH) broth for all bacteria. Escherichia coli (ATCC
®
 25922), Staphylococcus 
aureus (ATCC
®
 25923), Enterococcus faecalis (ATCC
®
 29212), Pseudomonas aeruginosa 
(ATCC
®
 27853), Staphylococcus saprohyticus strain 710826, Bacillus subtilis (ATCC
®
 6633), 
Acinetobacter baumannii (ATCC
®
 17978), S. aureus strain LAC (MRSA USA300-0114)
48
 and 
S. aureus strain BB2146
70
 were used. Each polymer was dissolved in DMSO, and this DMSO 
solution was diluted by 0.01% acetic acid to give 2-fold serial dilutions. An overnight bacterial 
culture was prepared by taking 2-3 bacterial colonies from a petri dish and placing them into 7 
mL of MHB with shaking at 37°C. After overnight growth, the bacterial culture was diluted by 
MH broth (OD600 = 0.1) and incubated at 37°C until the bacteria reached the mid-log growth 
phase, OD600 = 0.5-0.6 (1.5 -4.5 hours depending on bacterial strain). The bacteria culture in the 
midlog growth phase were diluted to the final concentration of OD600 = 0.001, which contains 
approximately 5 x 10
5
 cfu/mL. This stock (90 μL) was mixed with a polymer solution (10 μL) in 
a 96-well polypropylene microplate (Corning #3359). After incubating for 18 h at 37°C, the plate 
was examined visually to determine bacterial growth as the formation of bacterial palettes or 
increases in solution turbidity. The MIC was defined as the lowest polymer concentration at 
which no turbidity increase was observed for at least 2 out of 3 wells relative to the negative 
control, broth. As an additional negative control, 2-fold serial dilutions of DMSO, without 
polymer, were tested in the same conditions and showed no inhibitory effects, even at the highest 
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DMSO concentration (10%). All assays were performed in triplicate at least three independent 
experiments. The polymers in MH broth without bacteria did not show any precipitation, as their 
solubility was determined to be > 1000 μg/mL.  
Membrane Depolarization Assay 
Cytoplasmic membrane disruption was evaluated for polymers against S. aureus using the 
membrane potential sensitive dye DiSC3(5). A single colony of S. aureus was inoculated in 
MHB for 18h at 37°C, and mid-logarithmic phase cells (OD600 = 0.5 – 0.6) were collected. Cells 
were then resuspended in buffer (5 mM HEPES, 5 mM sucrose, 100 mM KCl, pH 7.2) to OD600 
= 0.05. A stock solution of DiSC3(5) in ethanol was added to S. aureus suspension (3 mL). The 
final dye concentration is 0.5 μM. The cell suspension with DiSC3(5) (0.5 μM) was stirred at 
room temperature until the stable reduction in fluorescence intensity was achieved due to 
quenching upon accumulation of dye on the S. aureus membrane. At 100 s, a solution of melittin 
(7.3 mg/mL, 5 μL) or polymer (various concentrations, 5 μL) in HEPES buffer was added to the 
bacterial suspension to give the final concentration (0.5 – 8x MIC). The fluorescence intensity 
was monitored with excitation and emission wavelengths of 622 and 670 nm, respectively. 
Finally, melittin was added after 200s to a final concentration of 2x MIC. As a control, the 
changes in fluorescence intensity of dye and polymers mixtures in buffer were determined. As a 
control, the changes in fluorescence intensity of DiSC3(5) and polymer mixtures in the absence 
of bacteria were determined 
Cell Leakage Assay 
Leakage of UV-absorbing cellular components from S. aureus and E. coli upon treatment with 
P7.7 was measured as a measure of membrane disruption by the polymer. The bacteria were 
regrown in MHB to give an OD600 > 0.8. The bacterial cells were harvested, and the pellets were 
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washed with PBS. The cells were then resuspended in PBS buffer. Cells were then incubated 
with the compound of interest (P7.7, lysostaphin, melittin, CTAB, or PBS for control) with 
shaking at 37°C. 2 mL of solution was removed at 2 hours, and centrifuged at 14,000 rpm for 10 
minutes to afford cell-free supernatant. The absorbance of cell-free supernatant was measured at 
260 and 600 nm.  
Antimicrobial Assay in Fetal Bovine Serum 
The minimum inhibitory concentration (MIC) of the AEMPs in the presence of fetal bovine 
serum (FBS) was determined as described above with modifications. Bacteria were grown 
overnight, diluted and regrown in MH broth at 37°C until the bacteria reached the mid-log 
growth phase. The bacteria culture in the midlog growth phase were diluted to the final 
concentration of OD600 = 0.00225. This stock (40 μL) was mixed with a polymer solution diluted 
in 0.01% acetic acid as for MIC (10 μL) and FBS or PBS (50 μL, 50% of total volume), and 
bacteria in MHB (40μL, OD600 0.00225) in a 96-well polypropylene microplate. After incubating 
for 18 h at 37°C, the plate was examined visually to determine bacterial growth as the formation 
of bacterial palettes or increases in solution turbidity. MIC was determined as described above.  
Hemolytic Assay 
Toxicity to human red blood cells (RBCs) was assessed by a hemoglobin release assay. RBCs (1 
mL) were diluted into PBS (9 mL) and then centrifuged at 2000 rpm for 5 min. The supernatant 
was carefully removed using a pipet. This procedure was repeated two additional times. The 
resulting stock (10% v/v RBC) was diluted 100x in PBS and the number of red blood cells was 
counted using a hemocytometer.  The original stock (10% v/v) was then diluted to 1.11 x 10
8
 
RBC/mL with PBS. This RBC suspension (90 μL) was then mixed with each of the polymer 
serial dilutions (10 μL) on a sterile 96-well round-bottom polypropylene microplate (RBC 
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concentration on plate is 1.0 x 10
8
 RBC/mL).  PBS (10 μL) or Triton X-100 (10 μL, 1% v/v) 
were added instead of polymer solution as negative and positive hemolysis controls, respectively. 
The microplate was incubated at 37°C in an orbital shaker at 180 rpm for 60 min. The plate was 
then centrifuged at 1000 rpm for 5 minutes. The supernatant (6 μL) was diluted into PBS (110 
μL) in a 96-well flat-bottom polystyrene microplate (Corning #3370) and the absorbance at 405 
nm was recorded using a microplate reader (Perkin-Elmer Lambda Reader). The fraction of 
hemolysis was defined as                 where A is the absorbance reading of the 
sample well, A0 is the negative hemolysis control (PBS buffer), and ATX is the positive hemolysis 
control (Triton X-100). Hemolysis was plotted as a function of polymer concentration and the 
HC50 was defined as the polymer concentration which causes 50% hemolysis relative to the 
positive control. The data were obtained in at least three experiments performed in triplicate. 
Bactericidal Kinetics 
Bactericidal kinetics was determined by inoculation of the polymers with bacteria in MH broth 
and colony counting on agar plates. An overnight culture of S. aureus ATCC
®
 25923 was 
regrown to the exponential growth phase (OD600 of 0.5 to 0.6) and diluted to an OD600 0.001 to 
give 8 mL of bacterial solution in a 15 mL centrifugation tube. To this solution, the polymer 
solution was added to a final concentration of two times the MIC value of each polymer. The 
tubes were incubated at 37°C in an orbital shaker at 180 rpm, and aliquots of solution (100 μL) 
were drawn at appropriate time intervals. After dilution by 10
5
, 10
4
, 10
3
, 10
2
, or 10-fold into PBS 
buffer, the dilutions were streaked onto agar plates and incubated at 37°C overnight. The 
colonies were then counted to determine the number of viable cells as colony-forming unit 
(cfu)/mL in the polymer solution. The data and errors are the average and standard deviation of 
two experiments, each performed in doublet (n = 4). 
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Resistance development in S. aureus 
The first MIC determination of AEMPs and two antibiotics Norfloxacin and Mupirocin against 
S. aureus ATCC
®
 25923 was performed as described above. Bacteria samples from triplicate 
wells (60 µL) at the concentration of one-half the MIC were removed, combined, and added to 
fresh MH broth (1.5 mL). The bacterial culture was regrown at 37°C to the mid-log growth 
phase (OD600 = 0.5 – 0.6). This culture was used to determine the MIC values of polymers again 
as described above. This experiment was repeated for 14 successive passages. This was repeated, 
for a total of two resistance experiments.  
Cell Culture 
Cytotoxicity experiments were carried out using the HEp-2 cell line and the COS-7 cell line. 
HEp-2 cells are human epithelial cells isolated from larynx carcinoma. It should be noted that the 
HEp-2 cell line is contaminated with HeLa cells derived from cervical cancer. HEp-2 cells were 
grown in minimum essential medium (MEM) supplemented with 10% heat-inactivated fetal 
bovine serum (FBS), pyruvate (1 mM), and nonessential amino acids (0.1 mM) at 37°C, 5% 
CO2, and 95% relative humidity. The doubling time of the HEp-2 cells in this supplemented 
medium is about 22-24 h. COS-7 cells are fibroblast-like cells derived from monkey kidney 
tissue. COS-7 cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 10% heat-inactivated fetal bovine serum, high glucose (25 mM), L-glutamine (4 mM), 
sodium pyruvate (1 mM) at 37°C, 5% CO2, and 95% relative humidity. The doubling time of the 
HEp-2 cells in this supplemented medium is about 35 – 48 hours.  
XTT Cell Viability Assay 
HEp-2 cells or COS-7 cells were seeded into the 96-well cell culture plates (Falcon #3072, USA) 
at a density of 1 x 10
4
 cells per well. After 20 h incubation, 24 h for COS-7 cells, the cell 
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confluence was about 50-60%, and the cell culture medium was replaced with serial dilutions of 
polymer stock solutions in an antibiotic- and scrum-free MEM. The viability of cells exposed to 
the polymers was assessed using a commercial kit (Cell Proliferation Kit II, Roche, USA). After 
a 24 hr exposure to polymers, the cells were washed once with PBS and then PBS (100 μL) was 
added to each well. A solution of sodium 3’-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis-(4-
methoxy-6-nitro) benzene sulfonic acid hydrate (XTT) and an electron-coupling reagent N-
methyl dibenzopyrazine methyl sulfate (PMS) were added to each well to give the final 
concentration of 0.2 mg/mL and 1.5 μg/mL, respectively. To assess the effect of polymers on the 
conversion of substrate, control wells containing only PBS and XTT with PMS were included. 
After a 4 hr incubation for HEp-2 cells or 6 hr incubation for COS-7 cells at 37°C in the presence 
of 5% CO2, the formation of orange colored formazan derivative produced by the metabolic 
cellular activity was determined by the absorbance at 450 nm (test wavelength) and 650 nm 
(background wavelength). The spectrophotometer was calibrated to zero absorbance using PBS 
without cells. The cell viability was determined relative to that of a control containing intact 
cells, which were exposed only to solvent.  The data are means and standard errors of 3 
independent experiments performed in triplicate (n = 9).  
In vivo Animal Testing 
The cotton rat nasal colonization model described by Kokai-Kun was utilized to determine the 
ability of polymers to decolonize S. aureus from the nasal environment.
110, 70
 Non-transgenic 
cotton rats (strain Hsd) were purchased from Harlen Laboratories. The protocol was approved by 
the Committee on Use and Care of Animals (UCUCA) of the University of Michigan (Permit 
Number: 10394). S. aureus (strain BB2146)
111
 was grown overnight in TSB, harvested by 
centrifugation, washed and resuspended in phosphate buffered saline (PBS). Cotton rats (3 - 5 for 
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each condition) were anesthetized, and a 10-µl aliquot containing 1 x 10
8
 colony forming units 
(CFUs) were intranasally instilled drop-wise equally between the two nostrils. After 3 days the 
animals were intranasally treated with an AEMP (P7.7 or P10) at 125 µg/mL or mupirocin at 400 
µg/mL (MIC = 0.2 µg/mL). Three days later the animals were sacrificed, the noses surgically 
removed, and S. aureus CFUs were determined. As a negative control, animals were exposed to 
PBS without polymer. Mupirocin was used as a benchmark for effective decolonization. The 
experiments for P3.1 and P5.5 were performed independently along with mupirocin and PBS 
controls, and the data for these controls were combined and used for statistical analysis.  
Osmoprotection Assay 
To estimate the functional diameter of the pores formed by the polymers, a MIC assay was 
performed in the presence of sucrose and polyethylene glycols (PEGs) with different molecular 
weights (400 – 4000). Sucrose and PEGS were prepared in PBS buffer and added to give a final 
concentration of 10 mM in the assay. Higher concentrations of PEG were not used because of 
possible difficulties concerning solubility and the viscosity of the assay media.  
Statistical analyses 
Statistics were performed using Student’s t-test. Results are expressed as mean ± standard 
deviation, unless otherwise indicated. 
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APPENDIX B  
Polymer Characterization 
1
H NMR Characterization of Homopolymers synthesized by RAFT polymerization 
Figure B-1 shows the chemical structure of the cationic methacrylate homopolymers and their 
1
H 
NMR peak assignments presented in Chapter 2. The NMR spectra of both the Boc-protected 
polymers as well as the deprotected polymers are shown below.  
 
Figure B-1. 
1
H NMR peak assignments for polymers with primary ammonium side chains 
synthesized by RAFT polymerization. 
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Figure B-2. 
1
H NMR of Boc-P9.9 (DMSO-d6) 
 
Figure B-3. 
1
H NMR of P7.7 (DMSO-d6) 
 
Figure B-4. 
1
H NMR of Boc-P11 (DMSO-d6) 
 87 
 
 
Figure B-5. 
1
H NMR of P10 (DMSO-d6) 
 
Figure B-6. 
1
H NMR of Boc-P19 (DMSO-d6) 
 
Figure B-7. 
1
H NMR of P12
 
(DMSO-d6) 
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APPENDIX C  
Stability of Polymer Endgroups: CPETC after exposure to TFA 
Trifluoroacetic acid (TFA) (100 μL) was added to 2-cyanoprop-2-yl ethyl trithiocarbonate 
(CPETC) (20.5 mg, 0.1 mmol). The reaction mixture was stirred at room temperature. Aliquots 
were removed at 0, 5 and 30 minutes, and the reaction was monitored by 
1
H NMR analysis in 
chloroform.  
The peaks of CPETC (3.35, 1.88, and 1.35 ppm) were monitored upon the addition of TFA. 
After 5 minutes, additional peaks appeared, indicating the formation of products likely due to 
degradation of CPETC. After 30 minutes, the multiplets around 3.3 and 1.34 ppm remain, while 
the singlet at 1.88 ppm has disappeared.  This demonstrates that the trithioester end groups of 
polymers might decompose during the deprotection of boc groups in the side chains of polymers 
under the acidic condition, possibly as a result of hydrolysis although the detailed mechanism of 
reaction is not clear at this point. 
 
 
Figure C-1. NMR of CPETC at t = 0 (CDCl3) 
  
 89 
 
 
Figure C-2. CPETC + TFA at t = 5 (CDCl3) 
 
 
Figure C-3. CPETC + TFA at t = 30 min (CDCl3) 
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APPENDIX D  
In vivo trial data 
As a preliminary assessment of the in vivo topical treatment of S. aureus infections using 
AEMPs, we chose a cotton rat nasal S. aureus colonization model. Two trials were performed: 
trial 1 involved 5 animals for P7.7, 3 animals for mupirocin, and 3 animals for PBS buffer 
(control); trial 2 involved 5 animals for P10.4, 5 animals for mupirocin, and 5 animals for PBS 
buffer (control).  
 
Table D-1. In vivo Testing 
Number of S. aureus BB2146 cells isolated 
 PBS Control Mupirocin P7.7 P10.4 
Trial 1 
3169 50 0 - 
2901 179 0 - 
3595 102 6 - 
- - 0 - 
- - 19 - 
Trial 2 
2019 3120 - 0 
2593 77 - 0 
3740 983 - 11 
1902 587 - 0 
2983 1276 - 65 
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